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Abstract
Renal transplantation is a life-saving procedure for patients with end-stage renal disease.
Persistent graft inflammation and fibrosis due to injury from repeated insults - both alloantigendependent and -independent - lead to chronic allograft dysfunction and long-term graft loss.
Ischemia-reperfusion injury (IRI) to the graft is an inescapable consequence of transplantation
and can result in significant delayed graft function (DGF). Tissue damage and graft dysfunction
resulting from transplant-associated IRI have been correlated with acute rejection and longterm graft loss. During IRI, dying renal proximal tubular epithelial cells (TECs) release proinflammatory mediators, worsening tissue damage and further potentiating injury by initiating
an auto-amplification loop of inflammation and cell death. Therefore, therapies that curtail this
auto-amplification loop may mitigate graft dysfunction and extend the lifespan of grafts.
Kidney injury molecule-1 (KIM-1) is a phagocytic receptor specifically upregulated on TECs
during renal injury, enabling them to engulf apoptotic and necrotic cells during acute kidney
injury. While KIM-1 can directly bind to apoptotic cells via phosphatidylserine, the clearance
of necrotic cells is enhanced by the opsonin, Apoptosis Inhibitor of Macrophage (AIM) protein.
The extent to which KIM-1 in the donor kidney contributes to renal transplantation has not
been well-studied. In this thesis, we studied the role of KIM-1 in the donor kidney on graft
outcomes following renal transplantation. We assessed the therapeutic potential of exogenous
recombinant AIM (rAIM) in mitigating transplant-associated IRI. Finally, we explored the
association between polymorphisms of the KIM-1 gene and DGF. Using a syngeneic murine
renal transplant model, we found that KIM-1 in the donor kidney protects against renal
dysfunction, inflammation, graft damage and death. Moreover, the protective effect of KIM-1
ii

was further enhanced with the administration of rAIM. Finally, we found that common genetic
variations of the coding region of human KIM-1 gene suppressed the phagocytic ability in vitro
compared to wild-type KIM-1. However, none of the variations were associated with increased
risk of DGF in our patient cohort. In summary, the findings reported in this thesis provide
further evidence of the protective properties of KIM-1 in transplant-related IRI and the viable
therapeutic potential of rAIM in renal transplantation.

Keywords
Apoptosis, Cell death, Danger Associated Molecular Patterns, Hepatitis A Virus Cellular
Receptor 1, Ischemia Reperfusion Injury, Kidney Injury and Repair, Kidney Injury
Molecule-1, Necrosis, Phagocytosis, Polymorphism, Renal Transplantation.
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Summary for Lay Audience
A kidney transplant has the potential to prolong the life of patients with kidney failure and
immensely improve their quality of life. A major limitation of transplantation is the limited
lifespan of the organs in the host. This is mainly due to cumulative damage sustained by the
organ during procurement/surgery (lack of blood flow to the organ) and the host immune
system (i.e. rejection). At the molecular level, this is caused by dying kidney cells which
“explode”, releasing their inflammatory cellular contents into the body which can serve to
activate the rejection process. Thus, the clearance of these dangerous remains is necessary.
In this thesis, I have characterized a protein called Kidney injury molecule-1 (KIM-1), which
help the remaining healthy kidney cells within the transplant to “eat” the surrounding dying
cells, thereby preventing the abovementioned inflammatory cascade and help repair the
damaged organ. In addition, I have documented the use of a potential therapeutic agent,
“AIM”, which when administered intravenously immediately following transplantation, can
compound the positive effect of KIM-1, to promote even faster and more effective clearance.
Finally, I translated my findings into humans and investigated whether different versions of
KIM-1 in the human population would affect the primary role of KIM-1, which could have
undesirable effects on its function during transplant resulting in patients requiring dialysis
within the first week- a problem known as delayed graft function (DGF). I uncovered that
different versions of KIM-1 protein found in the human population decreased its ability to
clear dying cells compared to normal KIM-1. However, the variation of KIM-1 was not
associated with increased risk of DGF. Taken together, these findings uncover a new
therapeutic target (KIM-1 and AIM) that may prolong kidney transplant survival.
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Preface
The following thesis takes you on a journey of the past 5 years of my tenure as a graduate
student. Starting as a Master's student, I found that research into the immune and nonimmune pathologies encountered in renal transplantation to be fascinating. I soon realized
that there was a considerable knowledge-gap regarding the fundamental types of injuries
sustained by the graft and how this impacts the lifespan of the transplanted kidney. Thus, I
decided to pursue a doctoral degree in the hopes of acquiring a more in-depth understanding
of the underlying mechanisms and potentially contribute to the development of novel
therapeutics aimed at improving the lives of transplant patients. This thesis entails the
culmination of that journey where I focused on the role of Kidney injury molecule -1 (KIM1) in renal transplantation.
This thesis may be of interest for transplant surgeons and nephrologists, or researchers
interested in ischemia reperfusion injury and transplantation. The overall aim of this thesis is
to understand the importance of renal transplantation in improving the long-term survival.
However, numerous limitations to renal transplantation remain, a major one being the limited
lifespan of kidney grafts. Hence, efforts to prolong graft lifespan and increase the likelihood
of post-transplant success, is dependent on understanding and targeting ways to minimize the
injury to the kidney graft. Using both mice kidney transplant model and human transplant
data, this thesis reveals the KIM-1 protein as a potential therapeutic target to prolong kidney
transplant survival.
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The aim of this thesis is to understand the pathophysiological mechanisms underlying
ischemia-reperfusion injury in renal transplantation and developing strategies to improve the
long-term survival of the transplanted kidneys.

xxv
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Chapter 1

1

Introduction

2

1.1 End-stage Renal Disease
Kidney damage and scarring (fibrosis) affects the ability of the kidney to filter and
remove waste and manage excess fluid. Persistent (and irreversible) kidney damage, also
known as chronic kidney disease (CKD), can lead to the gradual failure of the kidneys.
There are 5 progressive stages of chronic kidney disease where end-stage renal disease
(ESRD) is the final stage of CKD where both kidneys have irreversibly failed with less
than 15% of the kidneys functioning [1]. In the United States alone, there are
approximately 750,000 people suffering from ESRD and over 2 million people affected
worldwide. Alarmingly, the incidence of ESRD has been rising steadily at a rate of 5-7%
per year [2].
Kidney failure could manifest in the host in a variety of different ways including but not
limited to: protein energy malnutrition, abnormal metabolism of bone and mineral,
anemia, fluid retention, and uremia (accumulation of nitrogenous waste in the body) [1].
Thus, renal replacement therapy is vital for patients with ESRD. Currently, the two
available treatments are dialysis and kidney transplantation; the 5-year survival rates can
vary depending on the treatment type. Specifically, the 5-year survival rate was
approximately 42-52% among dialysis patients whereas transplantation conferred 7784% survival rates in recipients [2-5]. Furthermore, compared to dialysis patients,
successful transplantation recipients experience an increase in the quality of life, and are
faced with dramatically reduced health care costs [6-9]. Therefore, renal transplantation
is considered the optimal treatment choice for patients suffering from ESRD.

3

1.1.1

Renal Transplantation

Allo-, syn- and xeno-transplantations comprise of three theoretical forms of
transplantation. Xenogeneic or xeno-transplantation involves organ or tissue grafting
between two members of different species and is usually experimental in the context of
renal transplantation, whereas syngeneic transplantation involves grafting between
individuals that are genetically identical (i.e. identical twins). Allogeneic transplantation,
which is the most commonly performed type of transplantation in humans, is the grafting
of organs or tissues between 2 genetically different individuals from the same species. In
2019 alone, over 23.000 kidney transplantation was performed in the United States [2,
10] .
For a successful transplantation, a preoperative procedure needs to be conducted where
the recipients and the donors undergo ABO blood group matching and human leukocyte
antigen (HLA) compatibility assessment, as HLA mismatched transplant patients
exhibited considerably worse graft survival due to alloreactive responses in solid organ
transplantation [11, 12]. Upon successful matching, recipients will usually receive a
solitary donor kidney that is placed into their iliac fossa, a different location from the
native kidneys- this is termed a heterotopic transplant. This is because recipients usually
do not undergo bilateral nephrectomy except under specific circumstances (e.g. large
polycystic kidneys). Following the successful anastomoses of the donor artery to the
recipient external iliac artery and subsequent donor vein to the external iliac vein, the
donor ureter is then connected to the bladder of the recipients [13].

4

There are 2 types of renal transplantation performed worldwide: living donor vs.
deceased donor transplants. Live donor recipients receive a single kidney from a healthy
donor and generally live longer and experience better graft survival compared to
deceased donor recipients (Table 1-1) [5]. Living donation can take place between related
or unrelated individuals and can be directed (e.g. mother to son) or undirected (altruistic
donation). Deceased donor transplantations on the other hand, have 2 categories:
donation after circulatory death (DCD) and neurologic determination of death (NDD, or
also known as donation after brainstem death, DBD). DCD involves the donor kidneys
being retrieved from an individual who died naturally from cardiovascular causes, where
the heart stops beating resulting in the cessation of blood supply to the body. In contrast,
NDD involves the donor kidneys being acquired from individuals following
determination of neurologic death, where the heart continues to provide blood supply,
however no neurological activity is detected. Alternatively, expanded criteria donors
(ECD) are donors (DCD or NDD) that are above 60 years of age, or donors that are
between the ages of 50 and 59 with at least two of the following comorbidities including:
history of hypertension, death due to cerebrovascular accident, and/or terminal creatinine
(a metabolite of muscles which usually gets filtered by the kidneys) greater than
1.5mg/dl. Transplant recipients that received kidneys from ECD exhibited 70% increased
risk of graft failure compared to those who received kidneys from standard criteria
donors (SCD) [14].
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Table 1-1. Canadian kidney graft survival rates in renal transplant patients, 20042013.

Table adapted from CORR 2015 [5].

Numerous studies have shown that renal transplantation is the treatment of choice for
patients with kidney failure for many reasons including improved long-term survival,
lower overall cost when compared to dialysis and enhanced quality of life [7, 9, 15]. For
instance, successful transplant recipients no longer have to depend on dialysis for
survival, which can be as many as 3 times a week lasting 3-4 hours per session. However,
a major limitation of renal transplantation is that there is a tremendous shortage of donor
kidneys compared to the growing demand for organs [16]. Moreover, studies have
suggested that the demand is steadily rising by 8% each year [2] . In Canada, the number
of patients on the kidney transplant waitlist continue to increase, but due to limited
number of available donor organs, the number of deaths while waiting for a transplant
show a similar trend (Table 1-2) [5]. Likewise in the USA, there were more than 100,000
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ESRD patients on transplant waitlist in 2016 with only 20% of the patients able to receive
transplant surgery [2].
Table 1-2. Number of Canadians on waiting list and deaths on waiting list, 20042013.

Table adapted from CORR 2015 [5].

Aside from the scarcity of donor kidneys, another complication with transplantation is the
relatively finite lifespan of the graft. On average, the lifespan of kidney transplants are
12-20 years for living donor grafts and 8-12 years for deceased donor grafts [17].
Strikingly, approximately 30% of patients on the waitlist are those with failed transplants
[18]. Therefore, each available donor kidney is a precious commodity and steps should be
taken to ensure the success of each transplant procedure. This has led to the “one
transplant for life” movement [19]. One essential factor in ensuring donor kidneys remain
in optimal condition is to minimize the injury occurred during and after the
transplantation procedure. Unfortunately, preventing injury to the donor tissue remains a
challenging task as renal transplants are subjected to a series of injuries from both
alloimmune and non-alloimmune (both in the donor and upon transplantation) insults
which can culminate to chronic allograft dysfunction and graft loss [20, 21].
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1.1.2

Alloimmune Injury

Due to the highly polymorphic nature of major histocompatibility complex (MHC) genes,
or HLA genes in the humans, the physiological phenomenon of alloreactivity remains a
major obstacle to successful renal transplantation [22]. Over 15,000 different HLA alleles
have been discovered to date [23]. This is not to say that other non-conventional
molecules, such as the polymorphic MHC class I chain-related (MIC) genes, do not
contribute to alloimmunity. Allogeneic permutations between the donor and recipient can
trigger a vast array of physiological responses via the activation of alloreactive T and B
cells leading to graft inflammation and persistent infiltration of other immune cells such
as macrophages [24-26]. Alloimmune injury, which can be largely categorized as T cell(cellular) or antibody- (humoral) mediated, significantly contributes to persistent graft
damage over time [27]. Allograft rejection requires the activation of alloreactive CD4+ T
cells, which have been shown to be necessary and sufficient for rejection in animal
models. For example, mice deficient in CD4 + T cells were protected from renal
dysfunction, tissue damage and infiltration of neutrophils following renal IRI [28].
Dendritic cells (DCs), arising from both donor and/or recipient tissues, have been
identified as one of the key cell types involved in initiating alloimmune injury, whereby
upon activation, DCs migrate to secondary lymphoid tissues where they can further
activate alloreactive T cells and B cells [29-32]. Activated B cells can produce donor
specific antibodies (DSA) that can bind to the surface of the allogeneic HLA antigen
leading to graft rejection, also known as antibody-mediated rejection [22]. B cells can
also serve as antigen presenting cells (APCs) for cardiac allograft rejection [33]. Notably,
prior sensitization to alloantigens in the recipient, via blood transfusion, pregnancies
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and/or previous transplantations, results in an even greater humoral alloresponse [22, 34].
In the event that the triggered alloresponse also targets the one or more of the donor HLA
molecules expressed by the graft, the existence of donor-specific antibodies confers a
poor prognosis on prospective recipients [35]. The culmination of persistent alloimmune
injury to the graft from both effector T cells and/or donor specific antibodies, can lead to
acute or chronic rejection of the graft [21, 22] .

1.1.3

Non-alloimmune Injury

Non-alloimmune mechanisms of injury are another major component to graft injury that
can limit the success of a transplant, and comprises of multiple factors, including drug
toxicity, infection following transplantation, autoimmunity against cryptic epitopes in the
donor kidney, ischemic injury in the donor and/or recipient [27, 36]. Solid organ
transplantation recipients require to be on lifelong immunosuppression as it decreases the
likelihood of graft rejection. The most prescribed immunosuppressants include:
calcineurin inhibitors (CNI) (i.e. cyclosporine and tacrolimus), mycophenolic acid,
sirolimus, prednisone and basiliximab. Cyclosporine and tacrolimus have helped to
drastically improve graft outcomes [37-39] but are associated with acute and chronic
nephrotoxicity in renal and non-renal transplantation [39-41]. The pathophysiologic
mechanisms underlying CNI nephrotoxicity include direct and indirect effects (e.g. via
vasoconstriction, thrombotic microangiopathy) [41]. In addition, the suppression of the
host’s immune effector cells is the desired outcome, however this inevitably renders the
host more susceptible to viral infections and malignancies, which secondarily, can also
cause further damage to the graft [27, 42-44].
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Recipient factors that may curtail the lifespan of the renal transplant include the host’s
underlying comorbidities such as diabetes, lipid disorders, hypertension, and/or the
recurrence of the primary kidney disease (e.g. glomerulonephritis) [27, 45]. As a whole,
these are referred to as recurrence of original renal disease which includes primary renal
diseases (membranous glomerulonephritis), systemic diseases (e.g. amyloidosis) and
metabolic diseases (e.g. diabetic nephropathy). Various factors are included in the
viability of the organ category such as, donor age, living versus deceased donor, ischemia
time, and delayed graft function, all of which can contribute to promoting injury to the
graft [27, 46-48]. Thus, comprehensive therapies that target and address a plurality of
mechanisms of alloimmune and non-alloimmune pathologies may pave the way in
mitigating graft damage and ultimately prolonging the lifespan of the transplanted
kidneys, and its effect in the recipients.

1.1.3.1

Ischemia Reperfusion Injury

Ultimately, all donor kidneys are inescapably subjected to a specific type of injury during
the transplantation process, known as ischemia reperfusion injury (IRI), which is yet
another major hurdle to transplantation success. Ischemia is defined as the reduction of
blood flow whereas reperfusion is defined as the restoration of blood flow [49]. From the
retrieval of the donor organ to the implantation and successful anastomosis in the
recipients, the donor kidney is faced with varying degrees of IRI. For example, when
donor kidneys are obtained from a DCD donor, the kidneys will face a series of varying
periods of ischemia from the time the life support is withdrawn allowing for cardiac
arrest (and natural death) until and including the transplantation procedure. Specifically,
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during procurement while the kidney is still inside the body, the transplant tissue
experiences a brief period of warm ischemia when the clamp is placed prior to
nephrectomy. Donor kidneys subsequently undergoes a prolonged period of cold
ischemia during storage, while submerged in the universal University of Wisconsin (UW)
solution, at 4C until time for transplant. More recently, pulsatile hypothermic perfusion
was shown to mitigate the effects of DGF compared to static cold storage [50]. Next, the
donor kidney is then exposed to warm ischemia again during the period of implantation
and successful anastomosis inside the host. Finally, the reintroduction of the host’s blood
introduces reperfusion injury (Figure 1-1) [51].
In the case of kidneys obtained from DBD donors, the organ is faced with similar types
of cold and warm ischemia and reperfusion injury during procurement to successful
transplantation. One distinction, however, is because DBD donors do not have ceased
blood flow, they do not experience prolonged period of warm ischemia before
procurement, but rather experience a brief period warm ischemia because neurologic
death still alters the hemodynamics (Figure 1-1) [51, 52]. It is noteworthy that the major
consequence of IRI is DGF following transplantation which can severely impact the
health and longevity of the graft as well as negatively impact overall survival [47, 48,
53-55].
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Figure 1-1. Flow diagram representing the types of ischemia and reperfusion injury
the donor organ experiences from retrieval to implantation.
Flow diagram representing each event and type of ischemia that the donor graft endures
from the death of the donors (both DCD and DBD) until the restoration of blood flow in
the recipients. The red bar represents warm ischemia, and the blue bar represents cold
ischemia.
Figure adapted from Aitken et al. [51]
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1.1.3.2

Delayed Graft Function

The incidence of DGF is higher in patients receiving donor kidneys from DCD donors
compared to DBD donors (44% vs. 24%) due to prolonged warm ischemia time in DCD
kidneys [56]. Primarily caused by IRI, DGF is a complication where the transplanted
kidney fails to function readily following transplantation, and is clinically defined as the
need for dialysis within the first postoperative week [57, 58]. Some other clinical risk
factors influencing DGF include: donor/recipient sex, donor/recipient body mass index,
donor history of hypertension, donor age, and donor terminal serum creatinine [59, 60].
DGF often necessitates prolonged hospitalization while patients undergo multiple rounds
of dialysis which have tremendous financial considerations to both the health care system
and the patients [60, 61]. Additional consequences of DGF are increased morbidity and
mortality [60, 62-64]. In addition, the requirement to continue multiple rounds of dialysis
even after transplantation can have a negative psychological impact on the patients [65].
Moreover, recipients experiencing complications due to DGF are at a greater risk of
developing acute rejection, graft failure and development of chronic graft dysfunction,
which can lead to early death [60, 62, 66, 67]. Therefore, minimizing IRI and subsequent
DGF could tremendously improve both patient and graft outcomes following
transplantation.
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1.1.4

Animal Models of Renal Transplantation

Many animal models have been implemented to study renal transplantation, including the
use of large animals, such as pigs, to small animals like rats and mice [68, 69]. The
advantages of large animals, specifically pigs, to study renal transplantation include: the
close phylogenetical homology to humans compared other species, simplicity of
breeding, and comparable kidney size with humans. Notably, pig kidneys have been
shown to have more favorable outcomes when used in xenografts, compared to kidneys
from non-human primates [70, 71]. Unfortunately, the limitation of using pigs to study
renal transplantation is that the cost is exceedingly high compared to using small animals.
Small animal models especially mice are the most commonly utilized by researchers.
Although mice are genetically distant from humans compared to pigs, murine models are
of great use since sufficient information is already known about their immune system,
breeding is simple, they are economical, extensive reagents are already available to study
murine genes and proteins, and mice can be genetically modified allowing for
mechanistic studies [69]. For these reasons, this thesis focused on mouse models of renal
transplantation.
Considering the diverse etiologies that can give rise to the pathology associated with
transplantation, the genetic background of donor and host mice play a vital role in
establishing the pathogenesis of kidney injury during kidney transplantation. To study the
effect of non-alloimmune injury (i.e. ischemia reperfusion injury), syngeneic donor and
the recipient mice are necessary to eliminate any MHC mismatches and subsequent
alloimmune injury. In contrast, fully MHC mismatched (allogeneic) donor and recipient
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mice are required when assessing the effect of alloimmunity [72, 73]. Additionally, the
degree to which allogeneic mice are subject to MHC mismatch can be correlated with
post-transplant survival rates [72].
In mice, renal transplantation could be performed in one of two ways: 1) bilateral
nephrectomy of the native kidneys following transplantation or 2) nephrectomy of one
native kidney but leaving the contralateral native kidney in place with a transplanted
kidney. Bilateral nephrectomy allows the mice to solely depend on the transplanted
kidney for survival. Nephrectomy of only one native kidney following transplantation has
both advantages and limitations. This method is often used in long-term longitudinal
studies and chronic allograft injury models because mortality is not considered a risk
factor due to the presence of the healthy native kidney. On the other hand, because the
single native kidney is sufficient for maintaining adequate kidney function (adequate
glomerular filtration rate for sustaining health), potential deficiencies in the function of
transplant kidney cannot be delineated [72]. As such, the use of these animal models
should be tailored to the scientific question and potential translation of findings should be
made with the understanding of the limitations of each model.

1.2 Pathophysiology of Ischemia Reperfusion Injury
Tissue injury that invariably follows from ischemia is caused by the cessation of adequate
blood flow to the organ. The arrest or limitation of blood supply leads to deprivation of
oxygen (hypoxia) and nutrients, and the build-up of metabolic substances and carbon
dioxide [74]. This triggers a cascade of pathways leading to a significant reduction of
adenosine triphosphate (ATP) production and availability, and subsequent depressed
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activity of Na+/K+ ATPase and calcium pumps [75, 76]. The disruption of the ion balance
between the intra- and extra-cellular space and the build-up of lactic acid can lead to
acidosis, and ultimately causes the activation of phospholipases, proteases and
dysregulation of the cellular actin cytoskeleton [77-79]. Moreover, the disturbances of
cellular homeostasis, during ischemic injury, leads to breakdown of tight junctions, loss
of brush borders, and an influx of calcium leading to the overall impairment of kidney
function [80-82].
Upon reperfusion, following successful anastomosis, increased levels of oxygen and pH
is observed along with restored blood flow [83]. Reperfusion introduces additional injury
to the graft as excess influx of oxygen leads to the dysfunction of the mitochondrial
electron transport chain, and the activation of xanthine oxidase activity which causes
production of large amounts of harmful reactive oxygen species (ROS) [83, 84].
Consequently, ROS can damage and compromise the integrity of the cellular membrane
and cytoskeleton. Additionally, ROS increases mitochondrial calcium which forms the
mitochondrial permeability transition pore (mTPT) leading to cell death through various
mechanisms (Figure 1-2) [85] [86]. Taken together, both ischemia and reperfusion injury
during transplantation result in a cascade of pathways that contribute to cellular
dysfunction or death. Cell death from IRI can take on many forms including apoptosis or
necrosis contributing to renal dysfunction via different mechanisms including obstructing
the tubular lumen and triggering tissue-destructive inflammation [87, 88]. In addition,
loss of tight junction integrity can lead to back-leak of filtered toxins (and creatinine) into
the circulation.
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Figure 1-2. Flow diagram outlining major pathophysiology of ischemia reperfusion
injury leading to cell death.
Flow diagram representing each pathological event that a graft experiences during
ischemia reperfusion injury, which eventually leads to the death of tubular cells.

Figure adapted from Kalogeris et al. [85]
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1.2.1

Cell Death

Proximal tubular epithelial cells (TECs) comprise of more than 75% of renal
parenchymal cell mass, making it the most abundant renal cell type [89]. Due to their
nature of being hypo-perfused under homeostatic conditions, coupled with their high
energy demands while exhibiting poor glycolytic capacity, TECs are particularly more
susceptible to IRI compared to other cells types in the kidney [90-92]. Thus, IRI to the
TECs can trigger various forms cell death including but not limited to apoptosis,
necroptosis and necrosis.
Apoptotic cell death is a programmed cell death and can be triggered via intrinsic or
extrinsic pathways [85]. DNA fragmentation into discrete fragments of about 180-200
base pairs by specific nucleases is a distinctive characteristic of apoptosis [93]. Following
a sufficient stressor, intrinsic apoptotic cell death can be induced which involves the
translocation of the pro-apoptotic Bcl2 protein family, such as Bax and Bak, into the
outer membrane of the mitochondria. Consequently, the mitochondrial outer membrane
becomes permeabilized and results in the release of pro-apoptotic proteins such as
cytochrome c, endonuclease-G, and Smac/DIABLO [94, 95]. Cytoplasmic cytochrome c
can interact with apoptotic peptidase activating factor -1 (APAF-1), forming the
apoptosome which activates caspase-9 and subsequently caspase-3. Caspase-3, the master
regulator of apoptosis, proteolyzes numerous cellular proteins which ultimately results in
DNA fragmentation [96].
The extrinsic apoptotic pathway is triggered upon activation of TNF, Fas and TRAIL
receptors. Trimerization of these receptors occur once they are activated, which then
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forms the death-inducing signaling complex (DISC) by recruiting a number of proteins
including death domain containing proteins like FADD and TRADD. This complex then
activates caspase-8 and caspase-3 downstream [97, 98]. Cytoplasmic and nuclear
condensation and fragmentation as a result of caspase-3 leads to formation of apoptotic
bodies with externalization and exposure of phosphatidylserine (PS) on the outer, intact
membrane, which is the hallmark of apoptotic cells [99].
Unlike apoptosis, the morphological hallmarks of necrosis are characterized by their
cellular and organelle swelling, disruption of the plasma membrane, and the release of
intracellular contents [100]. Initially, necrotic cell death was considered to be a random,
unprogrammed processes in response to stress. However, growing evidence suggests that
necroptosis, programmed necrosis, which is the predominant from of cell death during
IRI, is regulated by activation of receptor interacting protein kinases (RIPK) [101-104].
Activation of RIPK, through various signaling cascades, phosphorylates mixed-lineage
kinase domain like protein (MLKL) resulting in the loss of plasma membrane integrity
and death by necroptosis [101, 105, 106]. Furthermore, studies have shown that blocking
RIPK signaling conferred a protective effect in a murine model of IRI [101, 107-109].
Aside from necroptosis, other regulated necrotic cell death pathways include pyroptosis
and ferroptosis. Of these 3 pathways, pyroptosis is considered to be the most
immunogenic cell death via the activation of caspase-1 [110]. Caspase-1 is responsible
for cleaving inflammatory cytokines including pro-IL-18 and pro-IL-1β into their active
forms, resulting in an enhanced proinflammatory environment compared to other
regulated cell death pathways [111]. Ferroptosis is less immunogenic than pyroptosis and
is an iron-dependent pathway of regulated necrotic cell death [112]. During ferroptosis,
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cystine deprivation results in glutathione depletion leading to the inhibition of glutathione
peroxidase 4 and lipid peroxidation, ultimately resulting in cell death by plasma
membrane rupture [110, 113]. Numerous studies that have targeted downstream of these
regulated cell death pathways exhibited successful protection against murine models of
IRI [114-117]. As such, necroptosis, pyroptosis, and ferroptosis are the most studied
regulated cell death pathways in ischemia reperfusion injury and transplantation.

1.2.2

Damage Associated Molecular Patterns

In contrast to apoptosis which is also referred to as “clean cell death”, necrosis is known
to be the most immunogenic form of cell death due to the rupturing of the plasma
membrane and leakage of intracellular contents into the extracellular milieu [118]. The
intracellular contents could include several highly immunogenic compounds such as,
high-mobility group box-1 (HMGB1), heat shock protein (HSP), histones, s100 proteins,
and uric acid. Although the aforementioned molecules serve a vital purpose when in their
natural intracellular location, these endogenous molecules can trigger proinflammatory
responses once spewed into the extracellular milieu or circulation. As a result, these
molecules have been identified as damage associated molecular patterns (DAMPs) or
danger signals [118, 119]. Extracellular DAMPs can be recognized by renal parenchymal
cells and innate immune cells via pattern recognition receptors (PRRs), whose activation
in turn triggers the downstream production of proinflammatory cytokines and mediators
[120]. The signaling pathway which links the extracellular DAMPs to the
proinflammatory response in cells in termed danger signaling. Moreover, DAMPs can be
released either passively or actively for instance during sepsis [121].
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HMGB1 is a nuclear protein that acts as a DNA chaperon to enhance chromatin folding
and transcriptional activation in all nucleated cells [122]. However, once released
(passively) by necrotic cells and uncleared apoptotic cells (undergoing secondary
necrosis) [123], HMGB1 can trigger activation of inflammation through binding to tolllike receptors-2, -4, and -9 (TLR2, TLR4 and TLR9) [124]. Through the activation of the
MyD88 signaling cascade, nuclear factor -B (NF-B), a master regulator of
inflammation, is activated leading to production of inflammatory cytokines (i.e. IL-1, IL6 and TNF-) and chemokines and subsequent recruitment of immune cells [125-127].
Importantly, HMGB1 has been shown to mediate kidney IRI and neutralizing HMGB1
protected against renal IRI in mouse models [128-131].
DAMPs, particularly HMGB1 has been shown play a key role in necroinflammation
[129, 131]. Necroinflammation describes the phenomenon of an auto-amplification loop
of cell death which describes the process of progressive inflammation initiated by cell
death begetting more cell death [113]. Specifically, necroinflammation is initiated
through the interactions of DAMPs released by few necrotic cells and the immune
response, resulting in inflammation which triggers progressively more necrotic cell death
which in turn elicit a greater immune response. The pathological consequence of
necroinflammation is tissue damage which manifests as graft damage and organ
dysfunction or failure [20, 113, 132]. Therefore, endogenous pathways that promote the
clearance of dying cells can mitigate necroinflammation and protect from tissue damage
in IRI. Agents that enhance such processes might be a novel therapeutic strategy in renal
transplantation where acute and chronic tissue injury is common.
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1.3 Kidney Injury Molecule-1
Kidney injury molecule-1 (KIM-1 in humans, and Kim-1 in mice), also known as T-cell
immunoglobulin mucin domain -1 (TIM-1), is a member of T-cell immunoglobulin
mucin (TIM) family [133, 134]. In humans, the TIM family consists of TIM-1, TIM-3,
and TIM-4, whereas in mice, the TIM family includes TIM-1 to TIM-8 [135-137]. KIM-1
is encoded by the gene hepatitis A virus cellular receptor-1 (HAVCR1), which encodes a
receptor for hepatitis A virus [138]. Thus, depending on the anatomical location and cell
type where this protein is expressed, it is referred to as HAVCR1 (in liver), TIM-1 (on
immune cells including T cells, regulatory B cells, and NKT cells) or KIM-1 (in kidneys)
[133, 139].
Activated CD4+ T cells, predominately Th2 cells, express TIM-1, where its ligation acts
as a co-stimulatory signal resulting in the promotion of cytokine production, T cell
proliferation, and the inhibition of tolerance [134, 140, 141]. TIM-4, a ligand for TIM-1,
regulates CD 4+ T cell activation and differentiation upon interaction by modulating the
Th1/Th2 cytokine balance [142]. Interestingly, the TIM-1: TIM-4 axis was reported to
exacerbate injury following IRI, and blocking this interaction ameliorated renal damage
[137].
Originally, KIM-1 was discovered as HAVCR1, a receptor for hepatitis A virus in
African green monkey cells [143]. The initial characterization of HAVCR1 described a
port of entry for hepatitis A virus into the cell [144]. Later, humans were found to possess
a homolog of HAVCR1 [145] which regulated the cellular entry of many viruses
including: Dengue virus (DV), Human immunodeficiency virus, hepatitis C virus, and
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Zaire Ebola Virus (EBOV) [146-149]. Shortly after the discovery of human HAVCR1, a
mouse homolog named KIM-1, was discovered on injured kidney tubular cells [150].
Therefore, the conserved nature of KIM-1 provides translational power across the species
barrier.

1.3.1

Polymorphism of KIM-1

The gene for KIM-1, HAVCR1, is highly polymorphic with thousands of variants
identified. This effect of the variability of HAVCR1 results in a highly heterogenous
human population where numerous different forms of KIM-1 can be observed [133, 141].
Indeed, previous studies have shown that susceptibility to a wide range of autoimmune
disorders and viral infections are linked with differential KIM-1 variant expression [142145]. Interestingly, in humans that expressed a select variant of KIM-1 which has a 6
amino acid insertion in the mucin domain producing a “longer variant”, exhibited greater
risk of susceptibility to severe hepatitis A [143]. The pathogenesis mediated by the longer
variant of KIM-1 in hepatitis A infection was found to be specific for both hepatocytes
and NKT cells. First, hepatitis A virus were able to more proficiently bind to hepatocytes
that expressed the longer variant of KIM-1 which increased the likelihood of infection.
Secondly, NKT cells which also express the HAVCR1 gene (known as TIM-1 in T cells),
were more responsive to virally infected hepatocytes and targeted them for destruction by
cellular-mediated cytotoxicity which exacerbated liver damage [143, 146]. In contrast
however, longer KIM-1 variants were found to be protective against atopy in some
individuals [147]. Moreover, individuals that exhibited that KIM-1 variant that caused
lower surface level expression exhibited delayed Human immunodeficiency virus
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infection [146]. Taken together, these and other studies, demonstrate the association
between genetic variations in HAVCR1 and the risks of disorders of immune
dysregulation such as asthma, rheumatoid arthritis, systemic lupus erythematosus, and
allergic rhinitis differs [145, 148-151]. Whether genetic variants of KIM-1 affect KIM-1
function in the kidney or are linked with susceptibility to renal injury following IRI has
not been studied to date.

1.3.2

Structure and Expression

HAVCR1 encompasses 14 exons and is located on chromosome 5p33.3 [139]. With a
length of 1095 bp, HAVCR1 mRNA encodes a type 1 cell surface glycoprotein that
consists of an extracellular immunoglobulin variable (IgV) domain, a mucin domain, a
transmembrane domain, and a short intracellular domain [150]. Extracellular
compartments of KIM-1 include N-terminal six-cystine IgV domain, and a highly
glycosylated mucin domain rich in threonine, serine and proline [162]. Intracellularly,
KIM-1 has a short C-terminal cytoplasmic tail that has a tyrosine kinase phosphorylation
motif (QAEDNIY) which is essential for signaling (Figure 1-3) [150, 163-165].
KIM-1 can be found on the apical surface of renal proximal TECs [150], however, a
healthy kidney does not express KIM-1 but transiently upregulates its expression
following an injury to the kidney [166]. Basal expression of Kim-1 has been reported in
Balb/c mice kidneys [167]. Upon expression on TECs, KIM-1 undergoes spontaneous
ectodomain cleavage and shedding, releasing the extracellular portion of soluble KIM-1
(sKIM-1) into the urine (or conditioned media in cultured TECs) [168-170]. The cleavage
of KIM-1 is considered to be performed by tumor necrosis factor- converting enzyme
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(TACE), also referred to as ADAM 17 [171]. At the protein level, a full-length human
KIM-1 has an apparent molecular weight of 104 kDa, but once cleaved, it generates a
soluble form of KIM-1 that is about 90 kDa in size and a small membrane bound form of
KIM-1 that is approximately 14 kDa [168]. KIM-1 is predicted to generate a 34 kDa
protein in the absence of any post-translational modifications. Murine Kim-1 is smaller in
size at ~60 kDa, where its size discrepancies with human KIM-1 may be explained by the
reduced number of glycosylation sites observed in mouse Kim-1 [168, 172].
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Figure 1-3. Structure of Kidney Injury Molecule -1
A schematic representation of the structure of KIM-1 which consists of an extracellular, a
transmembrane and an intracellular domain. The extracellular domain entails an IgV
domain which is a site for phosphatidylserine binding, and a highly glycosylated mucin
domain. The intracellular cytoplasmic domain contains tyrosine kinase phosphorylation
motif required for signaling.
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1.3.3

KIM-1 Function

The IgV domain of KIM-1 contains a metal ion dependent ligand binding site, where
phosphatidylserine, an “eat-me” signal on apoptotic cells, can bind [173]. Upon binding,
the KIM-1 expressing renal TECs are transformed into semi-professional phagocytes and
engulf apoptotic cells through a process known as, efferocytosis [153, 164, 174]. Using
murine models, our lab found that total genetic ablation of KIM-1 predisposed them to
more severe kidney dysfunction and damage following native renal IRI compared to
wild-type mice [175]. Similar results were reported when mice exhibiting mutation in the
KIM-1 mucin domain (KIM-1 Δmucin) which impairs binding to PS [164]. KIM-1
Δmucin exhibited greater renal dysfunction, renal inflammation, and mortality following
native renal IRI. The abovementioned would suggest that the primary function of KIM-1
in the kidneys is the removal of apoptotic cells which thereby limiting further
inflammation.
A secondary equally important function of KIM-1 is in the repair of denuded tubular
epithelium following acute injury. KIM-1 expression activates the extracellular signal
regulated kinase/ mitogen-activated protein kinase (ERK/MAPK) signaling pathway,
which in turn facilitates the migration and proliferation of TECs, promoting repair [176].
During an ischemic insult, KIM-1 was also shown to protect against cell death by
interacting with pro-apoptotic nuclear receptor 77 (NUR77) via the IgV domain [177].
An in vitro study has shown that following depletion of ATP and glucose to mimic
ischemic injury, the lack of KIM-1 expression resulted in higher levels of NUR77, and
increased amount of cell death [177]. Therefore, the clearance of dying cells during
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kidney injury, as well as promoting tissue repair by the neutralization of pro-apoptotic
factors, KIM-1 plays a crucial role in mitigating inflammation and tissue damage during
kidney injury.

1.3.4

KIM-1 Signaling

The conserved tyrosine kinase phosphorylation motif in the cytoplasmic tail of KIM-1 is
involved in downstream signaling pathways via engagement with protein kinases [163].
Upon binding of apoptotic cells to KIM-1, the intracellular tyrosine kinase of KIM-1 is
phosphorylated, leading to the interaction with p85. Subsequently, modulated by PI3K,
phosphorylation and activation of NF-B signaling is inhibited, thereby negatively
regulating inflammation (e.g. production of IL-6) (Figure 1-4) [140, 164].
Considering that phagocytosis is the primary function of KIM-1 in the kidney, it is of no
surprise that KIM-1 would be involved with cytoskeletal remodeling during the
internalization of apoptotic bodies. Previously, our group has shown that KIM-1 interacts
with T-complex testis specific protein 1 (Tctex-1), a dynein light chain protein, to
mediate the internalization of apoptotic cells via KIM-1 dependent efferocytosis [178]. In
addition, our laboratory has shown that during renal IRI, intracellular domain of KIM-1
directly interacts with alpha subunit of heterotrimeric G protein 12 (G12) directly and
suppresses its activation [179]. ROS produced during IRI activates G12 disrupting the
formation of tight junctions and zonula occludens-1 (ZO-1) on renal TECs during renal
repair through Src tyrosine kinases [180, 181]. Upon activation, KIM-1 acts to negatively
regulate G12 to limit its activity spurred on by ROS [179]. Hence, the molecular
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mechanisms involved in KIM-1- mediated protection against ischemia reperfusion injury
involves several signaling pathways and multiple intracellular proteins.

Figure 1-4. Diagram of the downstream signaling cascade pathway of KIM-1
inhibition of NF-B upon apoptotic cell binding.
Upon binding of apoptotic cells to KIM-1 via phosphatidylserine, p85 is recruited which
leads to the inhibition of NF-B activity which limits the production of inflammatory
cytokines such as IL-6, IL-1 and RANTES. KIM-1 Δ mucin are defective in binding to
apoptotic cells leaving NF-B unperturbed, resulting in inflammation.

Figure adapted from Yang et al. [164]

29

1.3.5

Clinical relevance of KIM-1

Following injury, soluble KIM-1 is shed into the urine upon cleavage of its ectodomain.
Because KIM-1 is upregulated during proximal tubule injury and not present in the
healthy human kidney, KIM-1 is regarded as a specific and sensitive biomarker for renal
acute kidney injury [182, 183]. KIM-1 is also aberrantly expressed in renal cell
carcinoma tumours and multiple kidney diseases [182, 184-186]. Urinary KIM-1 levels in
patients with chronic heart failure can be used as a prognostic clinical marker of
worsening renal function [187]. Of note, KIM-1 can also be detected in the blood upon
kidney injury which is thought to be due to the disruption of tight junctions and tubular
back-leaking [188]. In addition, growing evidence has shown that soluble KIM-1 is also
detected in the blood, which serves as a useful biomarker for acute and chronic kidney
disease and has been used to predict progression to ESRD in Type 1 diabetes patients
[189].
Studies have shown the utility of tissue expression of KIM-1 in numerous clinical
diseases. For example, KIM-1 expression, examined in the biopsies of transplanted
kidney of patients who developed graft dysfunction, is used to determine the degree of
injury [190]. Both urinary and membrane-bound KIM-1 expression can be detected in
patients suffering from chronic kidney disease (CKD) [139, 191] Surprisingly, transgenic
mice that were generated to expresses KIM-1 constitutively in TECs, developed
spontaneous CKD exhibiting significant amounts of kidney inflammation and fibrosis.
This result indicates that sustained expression of KIM-1 may be pathogenic, leading to
renal fibrosis and kidney failure [192, 193]. During the early stages of acute kidney injury
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(AKI), KIM-1 upregulation is protective due to its beneficial role of clearing dying cells,
initiating TECs repair, and limiting inflammation. However, sustained chronic expression
of KIM-1 may be harmful as could promote fibrosis, ultimately leading to CKD.
Therefore, modulating KIM-1 expression or function for therapeutic purposes for renal
injury must be done with caution and careful evaluation using representative animal
models.

1.4 Apoptosis Inhibitor of Macrophage
Apoptosis inhibitor of macrophage (AIM) protein (also referred to as CD5-antigen like,
CD5L), as the name suggests, is produced by tissue macrophages to aid in their survival
by inhibiting apoptosis [194]. AIM is a member of the scavenger receptor cystine-rich
domain superfamily (SRCR-SF) [195], and circulates in high concentrations in the blood
(~5g/ml in both humans and mice) bound to the Fc region of pentameric
immunoglobulin M (IgM) [196, 197]. A pentameric IgM forms a 50 groove where one
molecule of AIM can bind [197]. Although the size of AIM is relatively small (42 kDa in
mice and 37 kDa in humans), the assembly of AIM with IgM precludes AIM from renal
excretion due its large molecular size (~1000kDa) [198]. During AKI, IgM-bound AIM
dissociates where it can perform its function [196].
Human and murine AIM share considerable homology (~78%) consisting of conserved
protein sequences, however, they diverge in the degree of glycosylation. Human AIM
does not contain N-glycans, whereas mouse AIM bears heavy glycosylation.
Interestingly, modification of N-glycosylation in AIM has been shown to alter its
secretion and activity [199].
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1.4.1

Clinical relevance of AIM

Similar to KIM-1, AIM is also subject to cleavage allowing for the dissociation from IgM
which allows for renal excretion, and consequently detection in the blood and urine.
Although AIM cleavage is performed by an unknown protease, cleaved AIM is smaller in
size by 10 kDa which allows for the successful filtration through the glomerulus and
secretion into the urine [200]. The ability to detect AIM in the blood and urine makes it a
powerful biomarker and has been used to detect numerous diseases including: patients
with kidney injury, liver fibrosis in hepatitis C patients, atopic dermatitis, cirrhosis and
liver cancer [196, 201-203]. Once cleaved however, AIM cannot re-associate with IgM,
leading to its destabilization and subsequent activation where it can be free to be involved
in multiple disease states [196, 200].
The role of AIM in the progression of various diseases is an area of active research.
Typically, AIM exerts its effect on disease in its IgM-free form as AIM is inactivated
when associated with IgM. With respect to function, free AIM can be endocytosed into
adipocytes and hepatocytes through CD36 where it acts to inhibit the synthesis of
cytoplasmic fatty acids. Ultimately, this causes the decrease of the deposition of
triglycerol in cells which has been reported to prevent fatty liver progression and obesity
[204, 205]. Likewise, by inhibiting fatty acid deposition, AIM has been shown to have a
protective role in obesity related liver diseases and hepatocellular carcinoma [206].
Alternatively, AIM has also been shown to exert significant antimicrobial activity during
bacterial infection by it enhances the clearance of bacteria and fungi through opsonization
[207, 208]. Moreover, AIM has been studied in the context of multiple other diseases
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including chronic obstructive pulmonary disease, multiple sclerosis, inflammatory bowel
disease, and atherosclerosis [204, 209-212]. Finally, the modulatory function of AIM has
also shown promise in kidney injury following renal IRI [213].

1.4.2

AIM in Acute Kidney Injury

During AKI, AIM is released from its IgM pentamer bound form and is filtered through
the glomerulus where it can interact with healthy and injured tubular epithelial cells
[213]. To date, the specific mechanism behind the dissociation between AIM and the IgM
pentamer is yet to be determined. However, one may speculate that during IRI, the
homeostatic balance of ions in the body is altered, reducing the affinity of AIM for IgM.
Nevertheless, the phenomenon of AIM dissociation is essential for its protective role in
IRI. This is supported by studies showing that cats subjected to IRI are highly prone to
severe kidney injury because feline AIM is unable to dissociate from IgM due to a
particularly high affinity [214, 215].
Immunohistological staining of kidneys taken from both mice and humans suffering from
AKI revealed that IgM-free AIM predominately accumulates on intraluminal necrotic
debris [196, 200]. The primary role of AIM during renal injury is to prevent renal tubular
obstruction by coating dead cell debris promoting clearance, thereby reducing
inflammation and promoting repair. Dead cell clearance mediated by AIM is dependent
on KIM-1. AIM coating the intraluminal debris acts as an opsonin where KIM-1 can
recognize and directly bind necrotic cells conferring an enhanced ability of TECs to
phagocytose and clear the necrotic debris. This process excludes PS interactions with
KIM-1 as KIM-1 recognition of PS was not disturbed by AIM [213]. Although the direct

33

interaction of KIM-1 and AIM enhances KIM-1 mediated phagocytosis, the specific
mechanism regarding their binding remains unknown. Furthermore, when mice suffering
from native renal warm IRI were administered with recombinant AIM (rAIM), kidney
function and survival was markedly rescued [213]. Hence, testing the therapeutic benefits
of rAIM in renal transplantation is timely and has the potential to improve graft survival
given the impact of DGF (and IRI) on the kidney graft.
Taken together, rapid removal of cellular debris is vitally important in mitigating graft
damage and inflammation following renal transplantation. Large bodies of work support
KIM-1 as a potential target for therapeutic intervention in mitigating tissue injury
following native renal warm IRI. However, the extent to which targeting KIM-1 and or
AIM in a setting of renal transplantation where both warm and cold ischemia occurs still
remains to be explored.
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1.5 Rationale and Objectives
1.5.1

Rationale

Renal transplantation remains the optimal treatment option compared to dialysis for
patients suffering from kidney failure evidenced by marked improvements to health,
quality of life, and overall survival [7]. However, the major limitation is the paucity of
donor kidneys while the demand for kidney transplants is increasing. In 2013, out of the
3,300 Canadians on the kidney transplant waiting list, approximately 90 patients died
while waiting [5]. Moreover, due to the finite lifespan of the graft, about 30% of
transplant recipients require more than one transplant within their lifetime [18]. Taken
together, in the face of a constricted supply pool, coupled with a steadily rising demand
of donor kidneys, therapies that seek to minimize graft damage and ultimately prolong
the longevity of kidney grafts are vitally important.
Current knowledge describes that IRI, an avoidable consequence of kidney
transplantation process, results in DGF which ultimately imposes a negative impact of the
graft longevity and overall survival [47, 54]. Apoptotic and necrotic cell death is a
hallmark of IRI due to depletion of ATP and production of ROS resulting in deleterious
effects on the graft via necroinflammation [107, 113, 216]. Thus, one key strategy to
maximize transplantation success is to mitigate IRI-induced tissue injury, or promote
tissue repair following IRI [57].
Upregulation of KIM-1, a biomarker of renal tubular injury, on proximal TECs protect
against native renal warm IRI, restoring renal dysfunction, injury and overall mortality in
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mice via the clearance of dying cells [164, 175]. However, the role of donor KIM-1 in
renal transplantation where both warm and cold IRI are present has not been explored.
The objective of my thesis was to understand the multifactorial roles of KIM-1 in injury,
tissue repair, and inflammation following renal transplant IRI and to test whether KIM-1
can be targeted for potential therapeutics. Finally, I also sought to translate our findings
to clinical scenario by determining the functional consequences of naturally occurring
genetic variants of KIM-1 and their association with clinical DGF.

1.5.2

Objectives

Objective 1. Determine whether donor KIM-1 expression is protective during syngeneic
renal transplantation where severe cold and warm IRI is present using a murine model of
renal transplantation (alloantigen-independent i.e. IRI).
Objective 2. Determine whether targeting the KIM-1 pathway to enhance the clearance
of dead cell/debris via administration of recombinant AIM ameliorates IRI-induced
pathology in a murine model of renal transplantation.
Objective 3. Investigate whether 3 coding variants of KIM-1 that occur in high frequency
in the human population alter KIM-1 expression and/or its phagocytic function.
Objective 4. Determine whether the 3 KIM-1 variants (Objective 3) are associated with
increased risk of delayed graft function in human deceased donor kidney transplantation.
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recovery by regulating systemic
necroinflammation
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2.1 Introduction
Renal transplantation offers improved survival and quality of life compared to staying on
dialysis [1]. However, cold-ischemic reperfusion injury (cIRI) is unavoidable with renal
transplantation and contributes to overall length of hospitalization, risk of acute rejection,
and premature graft loss [2, 3]. Renal proximal tubular epithelial cells (PTECs) are highly
susceptible to ischemic injury as they comprise more than 70% of renal parenchymal
cells; PTECs also have high energy needs and possess poor glycolytic capacity [4]. Initial
injury is caused by ATP depletion, but subsequent activation of innate and adaptive
immune pathways leads to secondary graft damage [5]. Though kidneys have tremendous
capacity for repair, severe injury and/or unregulated inflammation can hinder this ability
[6].
The passive release of danger-associated molecular patterns (DAMPs, e.g. HMGB1)
from uncleared apoptotic (that undergo secondary necrosis) and necrotic cells activate
renal parenchymal and innate immune cells via pattern recognition receptors (PRRs) [7].
This can lead to the production of pro-inflammatory cytokines (i.e. IL-1 and IL-1) and
other mediators that further propagate tissue damage [8] and cell death by initiating an
auto-amplification loop [9, 10]. In addition, tubular obstruction from extrusion of dying
PTECs into the lumen can further contribute to renal dysfunction in IRI [11]. HMGB1 is
released into the circulation from many types of allografts after transplantation and
inhibiting its function has been shown to dampen alloresponses and even prolong graft
survival in several pre-clinical models [12-14].
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Kidney Injury Molecule-1 (KIM-1, also known as TIM-1 [15]) is a type 1 transmembrane
glycoprotein that is upregulated on renal TECs following injury [16]. We and others have
previously reported that KIM-1 is a phosphatidylserine (PS) receptor expressed on
PTECs, transforming them into semi-professional phagocytes for neighboring apoptotic
and necrotic cells [17-19]. Importantly, primary PTECs are entirely dependent on KIM-1
for efferocytosis [19]. While KIM-1 can directly bind and clear apoptotic cells expressing
PS [17], the binding and clearance of necrotic cells by PTECs requires the serum protein
(opsonin), Apoptosis Inhibitor of Macrophages (AIM/CD5L), which is freely filtered by
the kidney during acute kidney injury (AKI) [18]. KIM-1 expression, or lack thereof,
likely does not contribute to renal pathology in native conditions, as no differences in
kidney function or pathology between wild-type and KIM-1 deficient mice were observed
prior to IRI induction [20]. Work by our group and that of Bonventre confirmed that,
compared to wild-type mice, both KIM-1 deficient mice [20] and mice expressing a
mucin domain deletion (mutant) [21] are more prone to ischemic acute kidney injury
owing to two major mechanisms triggered by KIM-1 signaling upon engagement of
KIM-1 (on PTECs) by apoptotic cells or debris: (1) Initiation of an anti-inflammatory
program in PTECs mediated via interaction of KIM-1 with p85 and subsequent PI3Kdependent down-modulation of NF-κB [21]; (2) Inhibition of harmful G12 activation by
reactive oxygen species [20]. These studies suggested that KIM-1 primarily protected
mice from AKI by mediating intracellular signaling in PTECs.
Here we present new evidence of an essential role for donor-KIM-1 in regulating
systemic and local inflammation by preventing the release of HMGB1 from necrotic cells
and thereby protecting against transplant-related cIRI. The pathophysiology of tissue
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damage and its consequences to the host in the setting of renal transplantation is
fundamentally different from that of native kidney IRI (e.g. cold storage, multiple
episodes of warm ischemia, alloimmunity) [22, 23]. In addition, renal transplantation
affords a unique opportunity for targeted therapy for AKI because: (1) The timing of
initial injury is known in advance; (2) there are multiple stages of injury and delivery for
therapeutics (in the donor, storage solution, and/or the recipient). Therefore, we
investigated the role of graft KIM-1 in a syngeneic (life-sustaining) murine renal
transplantation model [24] with the ultimate aim of translating our findings to the clinic.

2.2 Materials and Methods
2.2.1

Animals

Wild-type C57BL/6 mice were obtained from the Charles Rivers Laboratory. C57BL/6
KIM-1 deficient mice (KIM-1-/-) were obtained from Dr. Andrew N. J. McKenzie (MRC
laboratory of Molecular biology, Cambridge, UK). KIM-1 deficient mice were generated
by targeted disruption of exon 2 of mouse havcr1-/- gene in mouse embryonic stem cells
as described previously [25]. All animal procedures were pre-approved by Western
University animal use subcommittee in accordance with the regulations of the Canadian
Council on Animal Care.

2.2.2

Renal transplantation

Male KIM-1+/+ C57BL/6 recipient mice were bilaterally (sequentially) nephrectomized
and transplanted with a single donor kidney from male KIM-1+/+ or KIM-1-/- C57BL/6
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mice in a single procedure [26]. This is a survival model. Donor kidneys were exposed to
35 min of cold ischemia. Mice with weight loss of 15% or clinical deterioration were
euthanized according to animal care protocols. Animals were followed 7 days posttransplant. Survival and renal function (serum creatinine) were monitored at 1, 3, and 7
days post-transplant. For each group, mice were euthanized at each time point to observe
and evaluate the graft.

2.2.3

Primary tubular epithelial cell culture

Primary tubular epithelial cells were cultured at 37C in 5% (vol/vol) CO2 by only
collecting the renal cortex of KIM-1 deficient and WT C57BL/6 mice. These cells were
maintained in DMEM (Invitrogen, Carlsbad, CA) and F12 (Invitrogen, Carlsbad, CA)
containing 10% FBS (Invitrogen, Carlsbad, CA), 1% Penicillin-streptomycin (Invitrogen,
Carlsbad, CA), 0.1% ITS (Invitrogen, Carlsbad, CA), 0.1% EGF (Peprotech, Rocky Hill,
NJ) and hydrocortisone (Thermo Fisher Scientific, Rockford, IL). Primary TECs were
used up until one passage. Hallmark appearance of TECs were confirmed by visual
analysis.

2.2.4

In vivo HMGB1 detection

Post-transplant serum was collected and serum HMGB1 was quantitatively determined
using Sandwich-enzyme immunoassay kit in accordance with its protocol (Shino-Test
Corporation, Tokyo, Japan). Multiskan GO software was used for quantification (Thermo
Fisher Scientific, Rockford, IL).

73

2.2.5

Phagocytosis assay/ In vitro HMGB1

Thymocytes were isolated from C57BL/6 mice at 3-6 weeks old. To induce apoptotic
cells, thymocytes were placed under UV light for 5 minutes followed by overnight
incubation at 37C in 5% (vol/vol) CO2 in DMEM media containing 1% Penicillinstreptomycin and 10% FBS. To induce necrotic cells, thymocytes were heat-killed by
incubating the cells at 65C for 16 minutes in PBS. For the phagocytosis assay,
approximately 1x106 primary TECs from Kim-1-/- and Kim-1+/+ C57BL/6 mice were
plated and subsequently co-cultured with either 1x106 healthy, apoptotic, or necrotic
thymocytes. After 24 hours of incubation at 37C in 5% (vol/vol) CO2, the conditioned
media were collected and analyzed for HMGB1 using western blots.

2.2.6

Western blot

Tissue sections were stored in 4% SDS. Pierce BCA Protein Assay Kit (Thermo Fisher
Scientific, Rockford, IL) was used to quantify isolated proteins from whole tissue
sections. We incubated the blots with mouse polyclonal KIM-1 (R&D Systems Inc.,
Minneapolis, MN) and mouse monoclonal GAPDH antibody (Santa Cruz Biotechnology,
Santa Cruz, CA). Western blots were developed and quantified using the FluorChem M
system (ProteinSimple, San Jose, CA).

2.2.7

RNA isolation and polymerase chain reaction

Tissue sections were collected in TriPure isolation reagent (Roche Diagnostic, Basel,
Switzerland) and total RNA was extracted. qSCRIPT cDNA SuperMix (Quanta
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Biosciences, Gaithersburg, MD) was used to generate cDNA. Real-time polymerase
chain reaction (RT-PCR) was completed using StepOnePlus Real-Time PCR System
(Applied Biosystems, Waltham, MA) and SYBR Green (Thermo Fisher Scientific,
Rockford, IL) detection was used to quantify relative expression. Primers (Integrated
DNA Technologies, Coralville, IA) used were: IL-6: F-5’-TACTCCTTCCTACCCCA
ATTTCC-3’ R- 5’- TTGGTCCTTAGCCACTCCTTC-3’; MIP-2: F-5’-CAAAGGCA
AGGCTAACTGACC-3’ R- 5’ACATCAGGTACGATC CAGG C-3’; TNF-: F-5’AGCCCACGTCGTAGCAAAC-3’ R- 5’ACAAGGTACAACCCATC GGC-3’.
GAPDH: F- 5’ TCAGCATCTCTAAGCGTGGT-3’ R-5’-ATGTTGTCTTC
AGCTCGGGA-3’ was used as the housekeeping gene.

2.2.8

Histology, immunohistochemistry

Tissue sections were stored in 10% formalin before sectioning. A renal pathologist,
blinded to the groups, scored the tissue sections that were stained with hematoxylin and
eosin (H&E) using a previously described semi-quantitative method [20]. Scoring
included: acute tubular necrosis (ATN) and tubular obstruction. For ATN, sections were
assessed for the presence of tubular necrosis, pyknotic nuclei, formation of proteinaceous
casts, brush border damage, proximal dilation and interstitial widening. Each section was
given an ATN score out of 5; 0= 0%, 1= <10%, 2= 11-25%, 3= 26-45%, 4= 46-75%, 5=
> 75% ATN [18]. Degree of tubular obstruction was measured by looking at intraluminal
debris of dead PTECs. Similarly, each section was given a score out of 5, with the same
scoring margins as ATN. Immunohistochemistry was performed on sections to visualize
apoptotic cells using anti-cleaved caspase-3 (Abcam, Cambridge, MA), infiltration of
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neutrophils using anti-myeloperoxidase (Abcam, Cambridge, MA), and macrophages
using anti-CD68 (Abcam, Cambridge, MA).

2.2.9

Immunofluorescence

Ethidium homodimer (EHD; Invitrogen, Carlsbad, CA) was used to quantify necrosis in
kidney graft sections. 5M EHD was injected into the renal artery for 10 minutes at a
speed of 1mL/min, followed by another 10 minutes of PBS at the same speed [14].
Frozen sections were used, and areas of necrosis were quantified using a FLUOVIEW
X831 confocal microscopy (Olympus, Tokyo, Japan). A total of 5 random nonoverlapping sections of the outer cortex were taken per slide. Quantification was done
using ImageJ software (National Institutes of Health, Bethesda, MD).

2.2.10

Statistical analysis

Log-rank test was used to determine the graft survival. One-way ANOVA was used for
multiple comparisons whereas t-test was used for unpaired values. Mann-Whitney test
was used when comparing nonparametric data. All these tests were carried out using
GraphPad Prism software (GraphPad Software Inc., La Jolla, CA). All data are presented
as means ± SEM, and p < 0.05 was used for significance.
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2.3 Results and Discussion
We characterized the expression of KIM-1 following transplantation. Graft KIM-1
expression was persistently upregulated even after 7 days post-transplantation, peaking
by day 1 post-transplant (Figure 2-1A, 1B). We then observed that absence of KIM-1
expression in the donor kidney resulted in significantly greater renal dysfunction as
indicated by higher serum creatinine values on day 3 (161.8 ± 39.8 vs. 15 ± 3.082
mol/L, p=0.0104; Figure 2-1C). Recipients of KIM-1-/- grafts also exhibited
significantly reduced 7-day survival compared to mice receiving wild-type grafts (5/5 vs.
3/12, p=0.0105; Figure 2-1D).
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Figure 2-1. KIM-1 expression on PTECs improves early graft function and survival.
C57BL/6 KIM-1 deficient or wild-type (WT) donor kidneys subjected to cold storage (35
minutes) were transplanted into syngeneic WT recipients. (A) KIM-1 protein expression
was confirmed in the kidney grafts of WT donor kidney recipients using Western blots.
GAPDH was used as a loading control. (B) Average densitometric ratio of Western blots
showing KIM-1 expression (n=3). (C) Serum creatinine was measured as a marker of
renal function at days 1 and 3 post-transplantation (*p < 0.05). (D) Survival of the renal
transplant recipients. Recipients of the KIM-1 deficient donor kidneys are denoted by
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dotted line (---), and recipients of WT donor kidneys are denoted by straight bold line
(*p=0.0105, log- rank, n=5-12/group).

Given the essential role of KIM-1 in the phagocytic clearance of apoptotic [27] and
necrotic cells in the kidney [19], we expected that the poor transplant outcomes
associated with donor KIM-1 deficiency would be associated with increased tubular cell
apoptosis and necrosis (secondary necrosis of uncleared apoptotic cells [27]) early after
transplantation. Mice transplanted with KIM-1 deficient donor kidneys exhibited
increased numbers of both apoptotic (16.67 ± 3.333 vs. 3.75 ± 2.394, p= 0.0018; Figure
2-2A) and necrotic cells (11.5 ± 1.041 vs. 0.5333 ± 0.1202, p= 0.0005; Figure 2-2B)
compared to mice transplanted with wild-type donor kidneys. In addition, we looked at
acute tubular necrosis (ATN) to determine the degree of graft injury. As shown in Figure
2-2C, KIM-1 deficient donor grafts revealed significantly greater ATN scores compared
to the wild-type grafts on day 3 post-transplantation (4 vs. 0.5, p=0.0286; Figure 2-2C).
We also observed persistent tubular obstruction, which contributes to kidney dysfunction
[11], more so in the KIM-1-/- grafts compared to the KIM-1+/+ grafts (3.5 vs. 0.5,
p=0.0286; Figure 2-2D). A lack of any difference at day 1 here is likely explained by the
fact that KIM-1 does not affect PTECs death due to cIRI [20, 21], but rather the removal
of debris after acute injury.
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Figure 2-2. Renal tubular epithelial cell death and graft injury between the two
donors following syngeneic renal transplantation.
(A) Apoptotic tubular cells were quantified using cleaved caspase-3 staining for early
apoptotic cells at days 1 and 3 post-transplantation. Apoptotic cells were counted and
averaged from 5 different fields at 400x magnification for each section (**p < 0.01). (B;
Top) Necrotic tubular cells were quantified using EHD. (B; Bottom)
Immunofluorescence images were taken at 400x magnification at day 3 posttransplantation (***p < 0.001). (C-E) Formalin fixed tissue sections were stained with
H&E and were scored by a renal pathologist blinded to their genotype. Slides were based
on a scoring system ranging from 0-5. 0= none, 1= < 10%, 2=11-25%, 3=26-45%, 4=4675%, and 5= >75%. (*p < 0.05, **p < 0.01, ***p < 0.001, n=3-5/group). (C) ATN score
(D) Tubular obstruction score (E) Images of H&E stained tissue sections at 3 days posttransplantation.
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An important, yet unanswered, question that remains is whether endogenous clearance of
apoptotic and necrotic cells, and reduction in the burden of secondary necrotic or necrotic
cells [28], would lead to a decreased release of DAMPs [27] and tissue inflammation.
Furthermore, while mice carrying global defects in efferocytosis pathways are known to
exhibit systemic autoimmunity [29, 30], systemic inflammation has not been attributed to
such defects during acute tissue injury. When we analyzed the grafts for markers of
inflammation, we noted that the absence of KIM-1 exacerbated the intra-graft
inflammatory response. There was significantly more granulocyte infiltration at both days
3 (1.2 ± 0.7348 vs. 0 ± 0, p=0.0060) and 7 (2.333 ± 2.333 vs,0 ± 0, p=0.0156; Figure 23A). Similarly, there was significantly higher macrophage infiltration at day 7 posttransplantation (10 ± 1.225 vs. 4.75 ± 0.4787, p=0.0072; Figure 2-3B) in KIM-1-/- vs.
wild-type grafts. In parallel, KIM-1-/- grafts also exhibited significantly greater expression
of IL-6 (45.08 ± 13.07 vs. 11.32 ± 0.8026, p=0.0419) and MIP-2 (108.6 ± 22.5 vs.
29.48 ± 13.22, p=0.0231; Figure 2-3C) compared to mice transplanted with wild-type
grafts at day 3 following transplantation.
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Figure 2-3. Absence of KIM-1 in the donor kidney exacerbates inflammation
following syngeneic renal transplantation.
(A-B) Tissue sections were stained for MPO or CD68 to detect graft-infiltrating
neutrophils and macrophages respectively, at days 1, 3 and 7 post-transplantation. The
images were visualized at 400x magnification. (A) Number of MPO + neutrophils/HPF
(*p < 0.05, **p < 0.01, n=3-5/group). (B; Top) Number of CD68+ macrophages /HPF
(**p < 0.01. n=3-5/group). (B; Bottom) Immunohistochemistry images of kidney graft
sections staining CD68 at day 7 post-transplantation. (C) Measurement of proinflammatory cytokines (IL-6, MIP-2, and TNF-) on day 3 post-transplantation using
quantitative RT-PCR. Data were normalized to GAPDH gene expression (*p < 0.05,
n=4).
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To formally test if the inability of PTECs to clear dying cells would lead to increased
passive release of HMGB1, we conducted an in vitro study where either healthy,
apoptotic (UV light-induced) [31] or necrotic (heat-killed) [19] cells were fed to primary
PTECs isolated from the kidneys of either KIM-1-/- or KIM-1+/+ mice, as previously
shown [20], and analyzed the conditioned media for HMGB1 after 24h (Figure 2-4A).
Virtually, none to very little HMGB1 was detected by Western blot when healthy cells
were fed to PTECs. In contrast, the conditioned medium from KIM-1-/- PTECs fed with
apoptotic cells (that underwent secondary necrosis after 24h) had significantly higher
relative ratio level of HMGB1 compared to wild-type PTECs (3.568 ± 0.7507 vs. 1 ± 0,
p= 0.0268; Figure 2-4B). As expected, when necrotic cells were fed to PTECs of either
genotype, no significant difference in the level of HMGB1 was detected, since we
previously showed that AIM (opsonin) is required for KIM-1-mediated clearance of
necrotic cells [18]. Next, we determined if the phagocytic clearance of dying cells by
KIM-1 would have any consequences on systemic HMGB1 levels. We performed an
enzyme-linked immunosorbent assay to quantify serum HMGB1 in vivo post-transplant.
Similar to our in vitro study, mice transplanted with the KIM-1 deficient kidneys
exhibited significantly greater serum HMGB1 on days 1 (50.75 ± 3.473, vs.31.67 ±
3.844, p= 0.0146), 3 (41.33 ± 1.856, vs. 23 ± 3.512, p= 0.0099), and 7 (59.67 ± 9.171, vs.
27.33 ± 4.256, p=0.033; Figure 2-4C) compared to mice transplanted with wild-type
kidneys.
During ischemic kidney injury, iNos-positive proinflammatory (M1) macrophages are
recruited into the kidney in the first 1-2 days within injury, whereas arginase-1 and
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mannose receptor-positive, (repair) noninflammatory (M2) macrophages predominate at
later time points.
Given that previous work demonstrated that HMGB1 can facilitate M1 polarization
during acute kidney injury [32], we therefore investigated whether the elevated HMGB1
levels in the KIM-1-/- mice correlated with increased M1 polarization in respective kidney
grafts. Interestingly, KIM-1 deficient donor grafts had significantly greater M1: M2 (CD
80: CD 206) ratio compared to the wild-type donor grafts on both days 3 (712.1 ± 166.2
vs. 220.7 ± 58.66, p=0.0494) and 7 (260.3 ± 27.42, vs. 158.3 ± 21.43, p=0.0428; Figure
2-4D) following transplantation.
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Figure 2-4. Absence of KIM-1 in the donor kidney leads to increased release of
HMGB1.
(A-B) PTECs isolated from either KIM-1 deficient or WT mice were fed either
thymocytes that were healthy, apoptotic, or necrotic. After 24 hours, conditioned media
was collected and HMGB1 release was measured. (A) HMGB1 release was confirmed in
the conditioned media using Western blots. (B) Relative quantification of Western blots
(*p <0.05, n=3). (C) In vivo serum HMGB1 was quantified using an ELISA kit at days 1,
3 and 7 days post-transplantation (*p < 0.05, **p < 0.01, n=3-4). (D) M1: M2
macrophage ratio using markers CD80 and CD206 respectively, on days 1, 3 and 7 posttransplantation (*p < 0.05, **p < 0.001, n=3).
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Renal replacement therapy is absolutely needed for patients with end-stage renal disease,
and renal transplantation is considered the best treatment [1]. However, the lifespan of
the kidney grafts is limited as they are subjected to persistent inflammation and fibrosis
due to repeated injury [1]. Graft inflammation can impair the induction of transplant
tolerance and enhances acute and chronic rejection [12]. Emerging data suggest that
necroinflammation triggered by cIRI may sustain graft inflammation via activation of
innate and adaptive (and alloimmune) immune pathways [33, 34]. DAMPs, specifically
HMGB1, have been shown to be a key mediator of this process [9, 14, 35].
HMGB1, an endogenous nuclear factor normally contained within the nucleus but
released when a cell undergoes necrosis or secondary necrosis, has been implicated in the
pathogenesis of IRI by stimulating TLR4 signaling. Through TLR4 signaling, HMGB1
has been reported to have a proinflammatory role during IRI, leading to organ damage
including the kidneys [9].
Kidney Injury Molecule-1 (KIM-1) is a type 1 transmembrane glycoprotein that is
specifically upregulated on the apical membrane of renal proximal tubular epithelial cells
(PTECs) following AKI [16]. Given our previous work demonstrated that KIM-1
upregulation on PTECs is required for clearing apoptotic or necrotic cells during acute
injury [18, 19], this study has uncovered a fundamental role for donor KIM-1-mediated
efferocytosis in inhibiting local and systemic necroinflammation.
In summary, we were the first to elucidate the protective role of donor KIM-1 in
mitigating tissue damage and cell death in post-renal transplant in a life-saving syngeneic
murine model. Since delayed graft function is a risk factor for rejection and poor long-
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term graft survival [3, 36], we provide the first evidence to support the use of therapeutic
strategies to enhance the clearance of apoptotic and necrotic cells [18], or HMGB1
signaling [35], during renal transplantation to improve overall graft survival.
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Chapter 3

3

Recombinant apoptosis inhibitor of macrophage
protein reduces delayed graft function in a
murine model of kidney transplantation

This chapter is currently under review:

Lee JY, Lian D, Haig AR, Suri RS, Miyazaki T and Gunaratnam L. Recombinant
apoptosis inhibitor of macrophage protein reduces delayed graft function in a murine
model of kidney transplantation. Submitted to PLOS ONE. Manuscript #: PONE-D-2027992
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3.1 Introduction
Renal ischemia reperfusion injury (IRI) is an unavoidable consequence of renal
transplantation. While most grafts will recover from IRI, prolonged cold and warm
ischemia may lead to delayed recovery and impaired graft function, with clinically
important consequences. Delayed graft function (DGF), defined as need for dialysis
within 7 days of renal transplantation, affects 20-50% of deceased donor grafts (DCD)
[1]. DGF not only results in acute morbidity and increased cost, but is increasingly
recognized as a risk factor for rejection and long-term graft loss [2, 3]. As prolonged
ischemia times are often unavoidable, especially with donation after cardiac death, a
better understanding of the mechanisms leading to tissue damage during IRI is needed in
order to develop effective therapeutic agents.
During renal IRI, ATP depletion and reactive oxygen species production leads to
apoptosis and/or, more predominantly, necrosis of the renal tubular epithelial cells
(TECs) [4-7]. To add insult to injury, dying cells lose membrane integrity, releasing
intracellular damage associated molecular patterns (DAMPs) into the extracellular milieu,
which trigger inflammation and promote further cell death. This positive-feedback loop
of inflammation and cell death – or necroinflammation – exacerbates tissue damage [8]
and potentiates both alloimmune - and non-alloimmune injury [7-9]. Although kidneys
have marked regenerative capacity, such unregulated inflammation and/or severe injury
can lead to irreversible allograft fibrosis [10, 11]. Thus, positing therapies that target
enhancing clearance of dying cells which would dampen the release of danger signals
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would break the feedback loop and may lead to protection against both graft damage
from IRI and alloimmune injury.
Kidney Injury Molecule-1 (KIM-1) is an endogenous transmembrane glycoprotein
transiently upregulated on proximal TECs during renal injury [12]. KIM-1 upregulation
on renal TECs during injury transforms them into semi-professional phagocytes capable
of clearing apoptotic cells (efferocytosis) [13], via direct binding of KIM-1 to
phosphatidylserine on apoptotic cells. Importantly, efferocytosis by proximal TECs is
solely dependent on KIM-1 [14]. We have previously reported that compared to wild-type
mice, KIM-1 deficient or KIM-1 mutant (KIM-1  mucin) mice exhibited greater renal
tissue damage, inflammation and mortality when their native kidneys were subjected to
warm IRI [14, 15]. In a different study, when we exposed donor kidneys from KIM-1
deficient to both warm and cold ischemia and then transplanted them into wild-type mice.
We observed greater renal and systemic inflammation as well as increased susceptibility
to renal dysfunction and tissue damage, compared to transplanted kidneys from wild-type
donors [16]. Taken together, these studies suggest that KIM-1 plays a protective role in
mitigating tissue damage by inhibiting necroinflammation [16].
While KIM-1 expression confers TECs with the capacity for direct phagocytosis of
apoptotic cells, clearance of necrotic cells by KIM-1 expressing TECs is enhanced
through the opsonization by the serum protein, apoptosis inhibitor of macrophage (AIM),
also known as CD5L [17]. AIM is produced by macrophages to support their survival
and circulates in the blood at high concentrations [18, 19]. Previous studies have
delineated the role of AIM in several conditions [18, 20]. At steady state, AIM is bound
to the much larger circulating IgM pentamer complexes, effectively preventing
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trafficking into the renal tissue architecture [17, 19-21]. However, during acute kidney
injury, AIM undergoes cleavage and dissociates from IgM pentamers through an
unknown mechanism [17, 19]. It is then filtered by the glomerulus and accumulates on
necrotic debris within renal tubules in both humans and in mice [17, 19, 21]. We have
previously demonstrated that, during moderate warm IRI of native kidneys, filtered AIM
accelerated renal recovery and improved mice survival in a KIM-1 dependent fashion
[17]. However, the anti-inflammatory and therapeutic effects of rAIM in renal
transplantation has not been studied.
Although KIM-1 expression is essential in the protection of sustained kidney damage and
function following renal transplant IRI, early kidney pathology and dysfunction was still
evident (Chapter 2) [16]. To this end, we tested whether administration of recombinant
AIM can be used as a potential therapeutic agent to further boost the protective effect of
KIM-1 and ultimately improve renal recovery after transplantation of kidneys exposed to
severe warm and cold ischemia. If found to be beneficial, exogenous AIM administration
could potentially be used to reduce incidence of DGF after transplantation of donor kidneys
which have inevitably been exposed to prolonged ischemia, thus improving long-term graft
outcomes in humans. We hypothesized that administration of exogenous recombinant AIM
would

augment

KIM-1-mediated

clearance

of

necrotic

cells,

mitigating

necroinflammation, tissue damage, and renal dysfunction after transplantation of kidneys
exposed to severe IRI.
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3.2 Materials and Methods
3.2.1

Renal transplantation/ AIM administration

We performed single kidney transplants of male C57BL/6 (B6) mice kidneys into male
B6 recipients following bilateral nephrectomy [22, 23]. Donor kidneys were exposed to
approximately 60 min of warm ischemia and 35 min of cold ischemia during each
procedure. Following kidney transplantation, recipients were administered a single 200 l
dose of either mouse rAIM (2mg/ml), or an equal volume of PBS intravenously via the
tail vein. Dosage of rAIM was previously determined [17]. Murine rAIM was generated
as previously described and provided by Dr. Miyazaki [17, 21]. All recipient mice were
viable at 2 days post-transplantation at which point they were euthanized, and graft tissue
and serum were collected. The primary outcome was renal function at 2 days and was
quantified by serum creatinine as previously described [16]. We assessed tissue damage
and local inflammation by histology; pro-inflammatory cytokine (IL-6, MIP-2, IL-1)
expression in the graft; and systemic inflammation by serum HMGBI.
B6 mice were obtained from the Charles Rivers Laboratory. All animal procedures were
pre-approved by Western University animal use subcommittee in accordance with the
regulations of the Canadian Council on Animal Care.

3.2.2

Histology/ immunohistochemistry

A renal pathologist, blinded to the treatment groups, scored the degree of tubular necrosis
and tubular obstruction on tissue H&E sections using a previously described semi-
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quantitative method as follows: 0 = 0%, 1 = <10%, 2 = 11-25%, 3 = 26-45%, 4 = 4675%, 5 = >75% [14]. Immunohistochemistry was performed on sections to visualize
apoptotic cells using anti-cleaved caspase-3, infiltration of neutrophils using antimyeloperoxidase antibody, and macrophages using anti-CD68 antibody. All antibodies
were obtained from Abcam, Cambridge, MA. Quantification was done by counting and
averaging from 5 different fields at 400x magnification for each section.

3.2.3

Inflammatory markers

Tissue sections were collected in TriPure isolation reagent (Roche Diagnostic, Basel,
Switzerland) and total RNA extracted. qSCRIPT cDNA SuperMix (Quanta Biosciences,
Gaithersburg, MD) was used to generate cDNA. Real-time polymerase chain reaction
(RT-PCR) was completed using StepOnePlus Real-Time PCR System (Applied
Biosystems, Waltham, MA) and SYBR Green (Thermo Fisher Scientific, Rockford, IL)
detection was used to quantify relative expression. Primers (Integrated DNA
Technologies, Coralville, IA) used were: IL-6: F-5’-TACTCCTTCCTACCCCA
ATTTCC-3’ R- 5’- TTGGTCCTTAGCCACTCCTTC-3’; MIP-2: F-5’-CAAAGGCA
AGGCTAACTGACC-3’ R- 5’ACATCAGGTACGATC CAGG C-3’; and IL-1: F-5’ACCTAGCTGTCAACGTGTGG -3’ R-5’ TCAAAGCAATGTGCTGGTGC-3’. We
used GAPDH: F- 5’ TCAGCATCTCTAAGCGTGGT-3’ R-5’-ATGTTGTCTTC
AGCTCGGGA-3’as an internal control.
Serum HMGB1 was quantitatively determined using Sandwich-enzyme immunoassay kit
in accordance with its protocol (Shino-Test Corporation, Tokyo, Japan). Multiskan GO
(Thermo Fisher Scientific, Rockford, IL) was used for quantification.
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3.2.4

Cell cultures

Human Embryonic Kidney 293 (HEK 293) cells and mouse kidney (Renca) cells were
obtained from America Type Culture Collection (ATCC, Manassas, VA) and cultured at
37C in 5% (vol/vol) CO2 incubator. HEK 293 cells stably expressing human KIM-1
pcDNA (HEK293 -pcDNA) were generated by transfecting with plasmid construct
encoding human KIM-1 using Lipofectamine® 2000 (Life technologies. Thermo Fisher
Scientific, Rockford, IL). Stable cell lines were maintained with geneticin (G418) sulfate
(Santa Cruz Biotechnology, Santa Cruz, CA) supplemented in DMEM (Invitrogen,
Carlsbad, CA) containing 10% FBS (Invitrogen, Carlsbad, CA), and 1% Penicillinstreptomycin (Invitrogen, Carlsbad, CA). Renca cells stably expressing mouse KIM-1
were generated by transducing with Lenti ORF particles, Havcr1 (Myc-DDK-tagged) or
LentiORF control particles (OriGene Technologies, Rockville, MD). These stable cell
lines were maintained with puromycin dihydrochloride (Sigma-Aldrich) and cultured in
RPMI-1640 medium containing 10% FBS, 5% PS, 0.1mM non-essential amino acids
(ThermoFisher Scientific, Waltham, MA), 1 mM sodium pyruvate (ThermoFisher
Scientific), and 2 mM L-glutamine (ThermoFisher Scientific). Hallmark appearance of
these cells was confirmed by visual analysis.

3.2.5

Phagocytosis assay/ Flow cytometry

We collected thymocytes from B6 mice and heat-killed them by incubating the cells at
65C for 20 minutes to induce necrosis. Necrotic thymocytes were verified by flow
cytometry analysis showing double positive staining for propidium iodide (Biolegend,
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San Diego, CA) and annexin V (Biolegend, San Diego, CA). Necrotic thymocytes were
labeled with human rAIM (100 μg/ml) (R&D systems, Minneapolis, MN) at 37C for 1
hour, or nothing. We then performed phagocytosis assay as previously described [17].
Briefly, approximately 1x106 HEK 293 cells were plated and fed 3x106 necrotic
thymocytes with or without human rAIM, or no thymocytes (control). After incubation
for 90 minutes at 37C in 5% CO2 incubator, cells were placed on ice to reduce nonspecific binding for 30 minutes, washed 3 times with ice-cold PBS and harvested. The %
phagocytosis, which represents the number of tubular cells that have phagocytosed the
necrotic cells, was analyzed using BD LSR II flow cytometer (BD Biosciences, San Jose,
CA). Similar procedure was performed using mouse Renca cells and mouse rAIM.

3.2.6

Statistics

Continuous variables (creatinine, inflammatory markers, % phagocytosis) and tissue
injury scores were compared between groups using one-way ANOVA/ Student’s t- and
Mann-Whitney U tests, respectively. All analyses were performed with GraphPad Prism
(GraphPad Software Inc., La Jolla, CA). All data are presented as means ± SEM; pvalues < 0.05 were considered statistically significant without adjustment for multiple
comparisons.
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3.3 Results
3.3.1

Renal Function and Tissue Damage

Recipient mice who received exogenous rAIM had significantly lower serum creatinine
at 2 days following renal transplantation compared to those who received PBS controls
(33.29 ± 10.83 vs. 192.7 ± 27.86 µmol/L, p=0.0019; Figure 3-1A). The rAIM treated
mice also exhibited significantly less tubular necrosis (1.5 vs. 3.5, p=0.0286; Figure 31B), less tubular obstruction (1.5 vs. 3.5, p=0.0286; Figure 3-1C and 3-1D), and less
apoptotic tubular cell death compared to PBS treated mice (2.5 ± 0.866 vs. 6 ± 0.7071,
p=0.0203; Figure 3-1E and 3-1F).
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Figure 3-1. Administration of recombinant AIM improves graft function and
mitigates graft damage.
Donor kidneys were transplanted into B6 wild-type recipients. Following transplantation,
recipients were injected I.V. with either 200 μl of rAIM (2mg/ml) or PBS. On day 2 posttransplantation, mice were euthanized and (A) Serum creatinine was measured as a
marker of renal function (B-D) Formalin-fixed tissue sections were stained with H&E
and were scored in a blinded fashion. Scoring system: 0 = none, 1= <10%, 2 =11-25%, 3
=26-45%, 4 =46-75%, and 5 = >75%. (B) ATN score, (C) tubular obstruction score (D)
H&E sections (E) early apoptotic tubular cells were quantified. Positive staining for
apoptotic cells were counted and averaged from 5 different fields at 400x magnification
for each section (F) Images of H&E -stained tissue sections. *p<0.05, **<p<0.01,
n=4~5/group.
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3.3.2

Local and Systemic Inflammation

Transplanted kidneys from mice treated with rAIM exhibited significantly less
macrophage infiltration (2.25 ± 1.315 vs. 10.75 ± 1.493, p=0.0052; Figure 3-2A and 32B) and granulocyte infiltration (3.5 ± 1.041 vs. 12 ± 2.041, p=0.01; Figure 3-2C and 32D) compared to those from PBS treated mice. Transcript analysis of transplanted
kidneys revealed that grafts from rAIM treated mice had significantly less expression of
pro-inflammatory genes: IL-6 (1.478 ± 0.3042 vs. 25.61 ± 8.566, p=0.0306), MIP-2
(19.79 ± 4.45 vs. 158.8 ± 57.65, p=0.0352), and IL-1 compared to grafts from PBS
treated controls (39.71 ± 7.822 vs. 142.1 ±34.11, p=0.0264; Figure 3-2E). We also
observed significantly decreased serum levels of HMGB1 in rAIM-treated mice
compared to PBS-treated mice (22.75 ± 6.098 vs. 40.48 ± 4.564 ng/ml, p=0.0450; Figure
3-2F).
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Figure 3-2. Recombinant AIM administration alleviates local tissue and systemic
inflammation following syngeneic renal transplantation.
(A-D) Kidney tissue sections were stained for CD68 or MPO to detect graft-infiltrating
macrophages and granulocytes, respectively. (A) Number of CD68+ macrophages/HPF.
(B) Immunohistochemistry images of kidney graft sections staining CD68. (C) Number
of MPO+ granulocytes/HPF. (D) Immunohistochemistry images of kidney graft sections
staining MPO. (E) Measurement of pro-inflammatory cytokines (IL-6, MIP-2ɑ, and IL1β) using quantitative RT-PCR. Data were normalized to GAPDH gene expression.
*p<0.05, **p<0.01, n=4/group. (F) Serum HMGB1 levels were quantified using ELISA.
p= 0.1, n=4-6/group.
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3.3.3

In vitro Phagocytosis

Renca cells stably expressing murine KIM-1 were able to engulf necrotic cells
significantly more in the presence of rAIM compared to without rAIM (17.7 ± 0.4726 vs.
12.9 ± 0.781%, p=0.0063; Figure 3-3A). Phagocytosis was found to be KIM-1 dependent
as Renca cells transfected with empty vector failed to clear necrotic cells.
Immunophenotyping by flow cytometry confirmed that the phagocytic target cells were
indeed necrotic cells as they were either double positive for annexin V and PI or single
positive for PI (Figure 3-3B). KIM-1 expression by the stably transfected Renca cells was
verified using Western blot (Figure 3-3C).
Similarly, in the presence of rAIM, human kidney cells expressing KIM-1 exhibited
significantly enhanced phagocytic activity of necrotic cells compared to controls (22.27 ±
0.4333 vs. 13.53 ± 0.7753%, p=0.0006; Figure 3-3D). Analogous to mouse Renca cells,
rAIM-mediated phagocytosis of necrotic cells was found to be dependent on KIM-1
expression as non-KIM-1-expressing human kidney cells failed to exhibit increased
clearance of necrotic cells in the presence of rAIM. KIM-1 expression on these cells was
verified by Western blot (Figure 3-3E).
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Figure 3-3. Recombinant AIM enhances the phagocytic uptake of necrotic cells by
both KIM-1 expressing mouse and human kidney cells.
Renca cells (mouse) or HEK293 (human) expressing KIM-1 or without KIM-1 were fed
necrotic thymocytes with or without rAIM (A-C). (A) Renca cells (mouse) after a 90minute incubation, % phagocytosis was quantified using flow cytometry. (B)
Immunotyping of necrotic cell populations. (C) Western Blots were performed
confirming the expression of KIM-1 on Renca cells. (D) HEK 293 cells (human) after a
90-minute incubation, % phagocytosis was quantified using flow cytometry. (E) Western
Blots were performed confirming the expression of KIM-1 on HEK293 cells. Histograms
are representative results of at least 3 independent experiments. All flow cytometry
experiments were analyzed using Flowjo X software. **p<0.01, ***p<0.001.
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3.4 Discussion
AIM has been reported to be of therapeutic relevance in various conditions including
obesity [18], autoimmune disease [24], and hepatocellular carcinoma [20]. Here, we
demonstrate the therapeutic potential of rAIM against transplant-associated IRI using a
clinically relevant model of kidney transplantation which incorporates severe forms of
both warm and cold ischemia. We found that a single dose of rAIM given to transplanted
mice almost completely normalized renal function at 48 h post-transplant and this was
accompanied by markedly reduced tissue inflammation and damage compared to
controls. Although AIM has been shown to protect against native renal warm IRI
previously [17], our study is the first to elucidate the anti-inflammatory effect of AIM in
a transplant IRI setting.
As the name suggests, AIM was initially identified as an apoptosis inhibitor which
ultimately supports the survival of macrophages [25]. Both humans and mice have
relatively high levels of serum AIM (5g/ml and 2g/ml, respectively) and similar
reported function [19]. With a half-life of 5 days for mice and 6 hours for humans, the
majority of circulating AIM is bound to the Fc region of pentameric IgM (>500kDa),
where one IgM pentamer houses one AIM. It is in this state where AIM is stabilized and
not filtered, albeit inactive. It is likely that the interaction between AIM and IgM-Fc is
due to the positively charged domain on the AIM protein being attracted to the negatively
charged area in the IgM-Fc [21]. However, during kidney injury, AIM dissociates from
IgM-Fc and is then filtered and accumulates on necrotic debris and interacts with KIM-1
thereby enhancing the phagocytic ability of KIM-1 to clear the necrotic debris [17]. The

115

mechanism as to how AIM dissociates from IgM-Fc is still unknown, but one speculation
may be that during kidney injury, altered homeostasis may disturb the charge differences.
However, this has yet to be investigated.
The main clinical manifestation of transplant IRI is DGF, resulting in increased
morbidity, prolonged length of stay and increased resource utilization [1, 3]. Decreasing
the incidence of DGF would thus be of major benefit. This is particularly true in the
current era where the use of DCD kidney donors, which is associated with the highest
rates of DGF, is approaching 20% in North America [26, 27]. To date, there are no
effective therapies to prevent DGF. Thus, if rAIM were to be equally effective in
humans as it was in mice, the therapeutic implications are likely to be of great
importance.
In addition to the effect of rAIM on graft function, our data also highlighted the potent
effect of rAIM administration on curtailing both graft and systemic inflammation (serum
HMGB1) caused by excess necrosis in the graft. Based on our previous work [16, 17], as
well as data presented in Figure 3-2, we conclude that the anti-inflammatory effect of
rAIM is mediated by the enhanced phagocytic clearance of necrotic cell debris within the
injured grafts. The ability to limit DAMP release from the damaged tissue may be
particularly important in the setting of allogeneic transplantation where extracellular
DAMPs have been shown to exacerbate alloimmunity [5, 16, 28]. Our syngeneic
transplant model was well-suited to studying the effects of rAIM on transplant-associated
IRI, but to test whether rAIM administration will mitigate alloimmune injury to the graft,
which can be persistent unlike IRI, is an important question.
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In addition to ameliorating inflammation, our work also demonstrated that rAIM
treatment decreased dead cell debris within the tubular lumen, which also likely
contributed to graft recovery given that tubular obstruction is a major mechanism
contributing to decline in glomerular filtration rate during AKI [10]. Finally, our finding
that rAIM augmented the phagocytic uptake of necrotic cells by human kidney cells
expressing human KIM-1 supports the translation of our work to transplant patients.
In summary, our study is the first to delineate the therapeutic role of recombinant AIM in
renal transplantation. Furthermore, our results demonstrate that KIM-1/AIM-mediated
clearance of dying cells mitigates graft damage, and inflammation, while improving early
graft function. Taken together, our findings suggest that the administration of
recombinant AIM may be used as a therapeutic strategy to improve graft outcomes in
kidney transplant patients.
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Chapter 4

4

Polymorphisms in HAVCR1 alter KIM-1
mediated phagocytosis
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4.1 Introduction
Renal ischemia reperfusion injury (IRI) occurs when blood flow to the kidney is
significantly reduced for a period of time followed by reperfusion. IRI pathology has a
two-pronged effect as ischemic conditions limits oxygen uptake resulting in ATP
depletion and the build-up of toxic by-products, whereas the restoration of blood flow can
produce harmful reactive oxygen species (ROS), leading to tissue damage [1, 2]. Notably,
IRI is one of the most common mechanisms of kidney injury in many clinical conditions
such as transplantation, sepsis and patients undergoing cardiac bypass surgery [3-5].
The destructive consequence of ATP depletion and ROS production during IRI cause
renal tubular epithelial cells (TECs) to be more susceptible to cell death via apoptosis or
necrosis [6, 7]. To add insult to injury, membrane integrity is typically compromised in
necrotic cells leading to the release of their immunogenic intracellular contents, also
known as danger, associated molecular patterns (DAMPs), into the extracellular milieu
which further exacerbates inflammation [8, 9]. This in turn can trigger an autoamplification loop of inflammation and subsequent cell death [10]. Thus, inducing rapid
phagocytosis and clearance of these dying cells may suppress inflammation and mitigate
kidney injury during IRI [11].
Kidney injury molecule -1 (KIM-1) is a cell-surface glycoprotein which transiently gets
expressed on TECs following kidney injury [12]. As a transmembrane protein, KIM-1
has its extracellular portion consisting of Ig-like and mucin domains that binds apoptotic
and necrotic cells allowing for the subsequent phagocytosis of neighbouring TECs [13].
KIM-1 binds directly to phosphatidylserine (PS) on apoptotic cells whereas phagocytosis
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of necrotic cells requires KIM-1 to interact with another protein that acts as an opsonin,
apoptosis inhibitor of macrophage (AIM) [14]. Using murine models, we have previously
shown that compared to KIM-1 deficient or KIM-1 mutant (KIM-1  mucin) mice, wildtype mice exhibited curtailed inflammation and limited tissue damage during renal
transplant and native renal warm IRI [15-17]. In addition, we found that phagocytosis of
PS expressing apoptotic cells was attenuated in KIM-1  mucin mice [17]. Therefore,
the alteration of the mucin domain or key residues required for PS binding may
profoundly affect the biological function of KIM-1.
The KIM-1 gene (HAVCR1), which was initially identified as the Hepatitis A Virus
Cellular Receptor 1 [18], is highly polymorphic and its variants are associated with
differential susceptibility to severe hepatitis A infection, allergy and autoimmune
disorders [18-20]. Considering the importance of the mucin domain to the functional
capacity of KIM-1, we hypothesized that in human populations, certain high frequency
HAVCR1 variants specific to the coding regions of the mucin domain would be
associated with altered phagocytic activity in vitro. This study provides novel insight into
the potential prognostic risk factors associated with KIM-1 variants and renal
transplantation.

4.2 Materials and Methods
4.2.1

Designing of the KIM-1 gene variants

Met158_Pro162del, Thr200del, and Thr207Ala mutations were created using pcDNA3
and the Quickchange lightning mutagenesis kit (Agilent Technologies) following the
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manufacturer’s directions. Primers were designed using Agilent’s primer design
program. Mutated plasmids were isolated from bacterial stock using a QIAprep spin
miniprep kit following the manufacturer’s directions (Qiagen, 27104). Mutations and
deletions were confirmed by DNA sequencing at the London Regional Genomics Centre.
Sequences were compared to Homo sapiens hepatitis A virus cellular receptor 1
(HAVCR1), transcript variant 1, mRNA NCBI Reference Sequence: NM_012206.3.
Primers used:
Met158_Pro162del

tgttccaacgacaacgactgttccaacgacaactgttc

Met158_Pro162del-antisense

gaacagttgtcgttggaacagtcgttgtcgttggaaca

Del200

cgacaacgagcattccaacaacaagtgttccagtg

Del200-antisense

cactggaacacttgttgttggaatgctcgttgtcg

Thr207Ala

gaacaaaggtagagacagctgttgtcactggaacact

Thr207Ala-antisense

agtgttccagtgacaacagctgtctctacctttgttc

4.2.2

Patients and Donor DNA sample collection

Total of 627 archived donor DNA samples from the histocompatibility laboratory at
London Health Research Centre (London, ON, CA) for all consecutive recipients of
deceased donor kidney transplants from 2008 to 2018 were collected. After verifying
DNA quality, Sanger sequencing and fragment length analysis were performed for the
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HAVCR1 variants, and genotype and allele frequencies were calculated by the members
of the Hegele Lab. Donor DNA was extracted from peripheral blood mononuclear cells
or splenocytes at the time of transplantation for HLA typing. Permission for use the
leftover DNA samples for this study was granted by the research ethics board of the
University of Western Ontario and Lawson Health Research Institute Research Ethics
Committee of the UMC.

4.2.3

Transfection of KIM-1 variants/ Cell cultures

Human Embryonic Kidney 293 (HEK293) cells were obtained from America Type
Culture Collection (ATCC, Manassas, VA) and cultured at 37C in 5% (vol/vol) CO2
incubator. HEK293 cells stably expressing wild-type human KIM-1 pcDNA (HEK293 pcDNA) were generated by transfecting with plasmid construct encoding human KIM-1
using Lipofectamine® 2000 (Life technologies. Thermo Fisher Scientific, Rockford, IL),
along with the 3 human KIM-1 variants described above. Stable cell lines were
maintained with geneticin (G418) sulfate (Santa Cruz Biotechnology, Santa Cruz, CA)
supplemented in DMEM (Invitrogen, Carlsbad, CA) containing 10% FBS (Invitrogen,
Carlsbad, CA), and 1% Penicillin-streptomycin (Invitrogen, Carlsbad, CA). Hallmark
appearance of these cells was confirmed by visual analysis.

4.2.4

KIM-1 surface staining/ Flow cytometry/
Immunofluorescence

Cells expressing human wild-type KIM-1 and the 3 variants were grown in media and
then harvested and stained with florescent anti-human KIM-1 antibody (AKG α-hKIM-
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1). They were then analyzed using BD LSR II flow cytometer (BD Biosciences, San Jose,
CA) for mean florescent intensity (MFI) to detect KIM-1 cell surface staining. For
immunofluorescence, cells were grown in normal media on cover slips then fixed with
2% paraformaldehyde. Cells were then incubated overnight with AKG α-hKIM-1
monoclonal primary antibody at 4C followed by secondary incubation with
fluorochrome-conjugated Alexa-Fluor 488® goat anti-mouse secondary antibody for an
hour at room temperature. All images were analyzed using a FLUOVIEW X831 confocal
microscopy (Olympus, Tokyo, Japan).

4.2.5

Phagocytosis assay/ Flow cytometry

Thymocytes were collected from 3-6-week-old C57BL/6 mice. Apoptosis was induced
by exposure to UV light for 7 minutes followed by overnight incubation in DMEM media
containing 1% Penicillin-streptomycin and 10% FBS at 37C in 5% (vol/vol) CO2.
Apoptotic thymocytes were verified by flow cytometry analysis showing single positive
staining for Annexin V (Biolegend, San Diego, CA) but negative for propidium iodide
(Biolegend, San Diego, CA). Apoptotic thymocytes were labeled with pHrodo, and
phagocytic activity was assessed as previously described [14]. Briefly, 1x106 HEK293
cells, with differential KIM-1 variant expression, were in co-culture with 3x106 pHrodolabelled apoptotic thymocytes. After incubation for 90 minutes at 37C at 5% CO2, cells
were placed on ice to reduce non-specific binding for 30 minutes and harvested. The %
phagocytosis, which represents the number of tubular cells that have phagocytosed the
apoptotic thymocytes, was analyzed using BD LSR II flow cytometer (BD Biosciences,
San Jose, CA).
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4.2.6

Western blot

KIM-1 variants’ cell lysates were stored in 4% SDS. Pierce BCA Protein Assay Kit
(Thermo Fisher Scientific, Rockford, IL) was used whereby isolated proteins from whole
tissue sections were quantified. We incubated the blots with human KIM-1 (AKG) and
mouse monoclonal GAPDH antibody (Santa Cruz Biotechnology, Santa Cruz, CA).
Western blots were developed and quantified using the FluorChem M system
(ProteinSimple, San Jose, CA).

4.2.7

Statistics

Percent phagocytosis and MFI (KIM-1 surface expression) were compared between
groups using one-way ANOVA. All analyses were performed with GraphPad Prism
(GraphPad Software Inc., La Jolla, CA). All data are presented as means ± SEM; pvalues < 0.05 were considered statistically significant without adjustment for multiple
comparisons.

129

4.3 Results
4.3.1

KIM-1 polymorphisms in the coding region have high
allele frequencies

Polymorphisms occurring in the coding region of a gene can either change the amino acid
sequence (nonsynonymous), or be silent (synonymous). Thus, we selected 3 known KIM1 nonsynonymous variants that are of known to have high allele frequencies in a global
population. Total of 627 donor DNA samples of recipients of deceased donor kidney
transplants at London Health Research Centre was obtained. The genotype and allele
frequencies of the 3 variants of our sample population were calculated which showed
striking similarities to the global population frequencies reported in GeneCards (Table 41).
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Table 4-1. Genotype and allele frequencies of 3 KIM-1 coding variants. Table of
distribution of genotype and allele frequencies of KIM-1 variants from 627 patients.

+/+: normal (no nucleotide changes/ deletion), +/-: WT/del or WT/nucleotide change
(heterozygous), -/-: del/del or nucleotide change/nucleotide change (homozygous).

We then generated constructs for these coding variants through site-directed mutagenesis
(Figure 4-1A and 4-1B). The 3 KIM-1 variants that we selected are as follows: KIM-11Met158-Pro162del (deletion of methionine to proline at positions 158-162); KIM-1Thr200del (deletion of threonine at position 200); and KIM-1Thr207Ala (substitution of
threonine with alanine at position 207) (Figure 4-1A). All of these polymorphisms are
located in the extracellular mucin domain of KIM-1 which is known to have an important
role in phagocytosis (Figure 4-1B).
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Figure 4-1. Generation of nonsynonymous KIM-1 variants.
(A) Diagram confirming the genotypes of the site-directed mutants corresponding to 3
nonsynonymous (coding) KIM-1- variants (KIM-1Met15_Pro162 del: deletion of
methionine to proline at positions 158-162; KIM-1-Thr200 del: deletion of threonine at
position 200; KIM-1-Thr207Ala: substitution of threonine with alanine at position 207).
(B) Schematic showing the phenotypic changes of the 3 (coding) nonsynonymous KIM-1
variants relative to wild-type.
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4.3.2

KIM-1 variants have altered cell surface KIM-1
expression

All 3 of the constructed KIM-1 variants expressed KIM-1 protein as efficiently compared
to the wild-type (Figure 4-2A). However, the 3 variants showed variable cell surface
KIM-1 expression in vitro (Figure 4-2B and 4-2C). Interestingly, HEK293 cells
transfected with KIM-1-Thr200del and Met158_Pro162del exhibited significant
upregulation and reduced expression of surface KIM-1, respectively, when compared to
the wild-type, whereas KIM-1-Thr207Ala showed comparable levels of KIM-1 cell
surface expression with the wild-type (Figure 4-2B). To further support our finding,
fluorescent microscope images stained for KIM-1 also showed congruent results (Figure
4-2C) as our flow cytometry data.
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Figure 4-2. KIM-1 variants have altered cell surface KIM-1 expression.
Functional analysis nonsynonymous KIM-1 variants. KIM-1 wild-type (WT) and KIM-1
variants (Thr200 del, Thr207Ala and Met158_Pro162Del) were expressed by transfection
in human embryonic kidney cells (HEK293). (A) Expression of KIM-1 protein in total
cell lysates by Western blot. (B) Expression of KIM-1 protein at the cell-surface by
fluorescently-conjugated human KIM-1 antibody via flow cytometry. Histograms are
representative results of at least 3 independent experiments. All flow cytometry
experiments were run on cytoFLEX cytometer and analyzed using Flowjo X software.
*p<0.05 (C) Fluorescent microscopic images of HEK293 cells transfected with KIM-1
variants positively stained for KIM-1.

4.3.3

KIM-1 variants have lower phagocytic capability

The functional capacity of our KIM-1 variants was assessed. Interestingly, we found that
all 3 coding variants exhibited significantly reduced phagocytic uptake of apoptotic cells
compared to the wild-type in vitro (Figure 4-3). Specifically, HEK293 cells transfected
with either Thr200del, Thr207Ala, or Met158_pro162del KIM-1 variants exhibited 25%,
57% and 10%, respectively, of the phagocytic ability of wild-type KIM-1. The corollary
to this finding would suggest that these HAVCR1 variants would significantly impair the
protective function of KIM-1 in IRI.
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Figure 4-3. KIM-1 variants have lower phagocytic capability.
HEK293 cells transfected with nonsynonymous KIM-1 variants. KIM-1 wild-type (WT)
and KIM-1 variants (Thr200 del, Thr207Ala and Met158_Pro162Del) were fed apoptotic
thymocytes. After 90-minute incubation, % change in phagocytosis (relative
phagocytosis of fluorescently labelled apoptotic cells) was quantified by flow cytometry.
Histograms are representative results of 6 independent experiments. All flow cytometry
experiments were run on cytoFLEX cytometer and analyzed using Flowjo X software.
****p<0.0001.
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4.4 Discussion
Renal tubular epithelial cells upregulate the surface expression of KIM-1 upon injury
which is then shed into the urine allowing for its detection as a biomarker for tissue
damage [21]. Indeed, KIM-1 has been reported to be used as a biomarker for kidney
injury and renal cell carcinoma [22, 23]. Additionally, KIM-1 is a receptor for
phosphatidylserine which allows the phagocytosis of neighbouring dying cells by the
KIM-1 expressing TECs which mitigates subsequent necroinflammation. Previous
studies have shown the protective role of KIM-1 against renal ischemia reperfusion injury
using various injury models [16, 17].
The KIM-1 gene (HAVCR1) is subject to high degrees of polymorphism, whereby
HAVCR1 variants have been linked with several clinical diseases including, hepatitis A
infections, and a diverse range of autoimmune disorders [18-20, 24]. KIM-1 has also
been shown to play an important role in renal transplantation, where its expression is
readily upregulated in donor kidneys upon engraftment, which is indicative of injury [25,
26]. Ischemia reperfusion injury is one of the major clinical risk factors that affect the
quality and longevity of donor kidneys [1, 27]. We have previously shown that KIM-1
expression in the donor kidney protects against renal transplant ischemia reperfusion
injury using a mice model [15]. Thus, our question was whether mutations in the KIM-1
gene would alter its functional ability. Here we found that the 3 high frequency coding
variants induced differential cell surface KIM-1 expression and universally decreased
phagocytosis compared to the wild-type. Interestingly, only the Thr200Del variant
exhibited increased cell surface KIM-1 expression, however its phagocytic ability was
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still significantly reduced. It is possible that mutations in the mucin domain of KIM-1
allows for the binding of PS-expressing apoptotic cells but prevents the internalization
and subsequent clearance. Future investigations into the specific mechanisms that would
elucidate the diminished functional capacity of KIM-1 variants are warranted. Although
our data highlights the association between genetic variation and phagocytosis in vitro,
the role of these KIM-1 variants in vivo with respect to renal transplantation, graft
damage, and signaling is unknown and requires further examination. Our findings have
translatable implications, since all 3 variants were found to be of high frequency in
human donor kidneys. It would be important to analyze whether the KIM-1 variant
incidence would correlate with prognostic outcomes of kidney graft success.
In summary, our study is the first to delineate the functional role of KIM-1 gene variants
in vitro. Furthermore, our findings show that the 3 distinct mutations in the coding region
of HAVCR1 have altered surface expression but universally lead to significantly reduced
phagocytic capability. Taken together, our findings suggest that mutations in the KIM-1
gene may lead to increased risk of allograft rejection following renal transplantation.
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5.1 Introduction
Delayed graft function (DGF), defined as the need for dialysis with in the first 7 days
post-transplant surgery, is a common complication faced by renal transplant recipients
[1]. The incidence of DGF can vary from 20-30% in deceased donor kidney recipients,
reaching >40% in recipients of donation after circulatory death (DCD) donors [2].
Patients with DGF have significantly poorer clinical outcomes, experiencing prolonged
hospitalization, higher risk of developing acute rejection, and poor long-term graft
survival [3-5]. Clinical risk factors of DGF include both donor and recipient
characteristics but specific prediction tools are lacking. Some of these factors include
duration of cold ischemia, DCD donor, duration of dialysis, terminal donor creatinine,
donor and recipient sex, age, and body mass index (BMI), and recipients’ race [5-7]. A
growing body of experimental literature suggests that donor kidney-intrinsic genes also
profoundly influence DGF risk [8, 9].
Ischemia reperfusion injury (IRI) is a largely unavoidable consequence of transplantation
and is a major cause of DGF [9]. ATP depletion and the subsequent production of
reactive oxygen species (ROS) during IRI induces vast amounts of tubular epithelial cells
(TEC) to undergo sublethal injury or death via apoptosis or necrosis. Severe IRI leads to
acute tubular necrosis whereby necrotic debris collects within the tubules and obstructs
the flow of ultrafiltrate [10]. As a consequence, glomerular filtration rate declines, and
may lead to delayed graft function [11, 12]. Secondarily, IRI can enhance the
immunogenicity of the allograft by inducing the upregulation of HLA molecules and costimulatory on the surface of endothelial cells and antigen presenting cells (APCs)
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(passenger leukocytes or infiltrating APCs), respectively which can engage the adaptive
immune system to exacerbate alloimmune injury [13]. The underlying mechanism
includes the release of danger signals such as High Mobility Group Box-1 (HMGB1),
either passively from necrotic cells (e.g. TECs) or actively from injured and/or inflamed
cells (e.g. macrophages), which then act on pattern recognition receptors on various
parenchymal or innate immune cells within the injured graft to promote
“necroinflammation” [14-16].
Kidney injury molecule -1 (KIM-1) is a glycoprotein whose expression is upregulated on
the apical surface of renal proximal TECs following kidney injury [17]. The principle
function of KIM-1 is to mediate the clearance of dying (apoptotic and necrotic) cells. The
immunoglobulin variant (IgV) domain of KIM-1 directly recognizes and binds to
phosphatidylserine (PS), which allows for the phagocytosis of the apoptotic cell bodies
which display PS on their outer membrane for removal [18, 19]. In addition, KIM-1
expression enhances the uptake of necrotic cells through an opsonin, apoptosis inhibitor
of macrophage (AIM) protein that is filtered by kidneys during IRI and binds to necrotic
debris within the tubules [20]. This was evident in mice deficient for KIM-1, as they
experienced significantly higher inflammation and tissue damage following native kidney
warm IRI [19, 21]. Similarly, mice with a mutation in the mucin domain (KIM-1 
mucin) of KIM-1, rendering them incapable of binding to apoptotic cells and mediating
their phagocytic uptake, are more susceptible to IRI compared to wild-type mice [22]. In
the context of a mouse model of renal transplantation, KIM-1 deficiency in donor kidneys
aggravated graft damage and resulted in severe renal function leading to lower overall
survival [23]. Thus, these findings suggest that, not only the expression of KIM-1, but its
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functional activity in TECs is essential in mitigating graft damage from IRI and
improving graft function following renal transplantation.
The gene that encodes KIM-1 was initially identified as Hepatitis A virus cellular
receptor-1 (HAVCR1), since KIM-1 was discovered as the cellular port of entry for
Hepatitis A virus. KIM-1 is highly polymorphic with >5000 variants reported to date [24,
25]. A large number of the identified human HAVCR1 polymorphisms are located within
exon 4 which codes for the mucin domain. The degree of polymorphisms in exon 4 has
may be driven by natural selection pressure driven by infection with Hepatitis A Virus
[26]. Notably, a polymorphism resulting in a 6-amino-acid insertion in KIM-1/HAVCR1
(157insMTTTVP) was associated with severe Hepatitis A Virus-induced liver disease
[25]. The long allele of KIM-1 was shown to a more effective receptor for HAV than the
short allele. Several other HAVCR1 polymorphisms have been linked with increased
susceptibility to hepatitis C infection, asthma, and eczema [25, 27-29]. Thus far, no
studies have investigated the effect of HAVCR1 polymorphisms on outcomes in acute
kidney injury or transplant-associated IRI (e.g. DGF).
It is increasingly recognized that donor kidney-intrinsic genetic factors influence the
severity of DGF [8, 30]. Previous studies have examined whether certain donor- and/or
recipient-derived polymorphic genes affect the outcome of transplanted kidneys [6, 31],
but to date, few genetic determinants have been identified that predict the risk of DGF in
patients [32]. Moreover, to our knowledge, no studies have associated genetic
polymorphisms that encode for defects in proteins involved in the pathophysiology of
acute kidney injury with altered clinical outcomes. Given that KIM-1-mediated
phagocytic clearance of apoptotic and necrotic cells mitigates IRI and the absence of

146

KIM-1 in the donor kidney led to graft dysfunction and damage in a syngeneic mouse
model of renal transplantation [18, 19, 22, 23], we investigated whether functional
polymorphisms in affecting KIM-1 function in the donor kidney plays a role in DGF
following deceased donor kidney transplantation. To this end, we have identified three
coding variants of human HAVCR1 encode for KIM-1 proteins that are significantly
impaired in their phagocytic activity (Chapter 4 of this thesis). Based on these findings,
we conducted a retrospective cohort study of patients who received a deceased donor
kidney transplant to determine if those who received a kidney from donors with one or
more KIM-1 variants are at increased risk of developing DGF.

5.2 Materials and Methods
5.2.1

KIM-1 variant selection

As correlational studies that examine the association between the phagocytic function of
KIM-1 and clinical outcomes are lacking, we identified high-frequency allelic KIM-1
variants that have been previously reported to have an association in non-renal diseases
[26, 33, 34]. KIM-1 variants with Minor Allele Frequencies (MAF) between 0.25-0.5
from North American populations previously reported from GeneCards were chosen. In
total, 3 KIM-1 (non-synonymous) variants located in the coding region were selected. We
chose to study these KIM-1 variants as a follow-up study to Chapter 4 based on the
observed significant reduction on phagocytic function.
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5.2.2

Population

The London Health Sciences Centre (LHSC, London, Ontario, Canada) Renal
Transplantation Program has performed 49-126 renal transplant surgeries annually since
1995. Since 2008, DNA samples from kidney donors have been collected and are stored
at the LHSC Histocompatibility Laboratory. For this study, we included all adults >18
years old who received a kidney transplant from a deceased donor between 2008 – 2018.
Patients who had undergone combined transplantation with more than one organ (i.e.
kidney/liver or kidney/pancreas), or who had missing, or unusable donor DNA samples
were excluded. A total of 627 recipients met eligibility criteria. As this was a
retrospective study with collection of de-identified data, patient consent was waived. The
study was approved by Western University’s (HSREB# 107181) and Lawson Health
Research Institute’s Research Ethics Boards (R-15-563).

5.2.3

Data collection

We reviewed recipient medical charts for baseline demographic information, duration of
end-stage renal disease, type of dialysis, comorbidities, body mass index, and baseline
laboratory values. We collected post-operative outcome data, including:
immunosuppressive agents used, daily creatinine values, need for dialysis, and hospital
length of stay, and graft rejection. All data was obtained from the patient’s electronic
medical record (PowerChart) for transplants performed since 2012. For those who
received transplants prior to 2012, paper medical charts were retrieved and reviewed.
Information on donor age and comorbidities, and warm and cold ischemia times were
obtained. Each recipient donor pair was assigned a unique study ID number and all data
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was entered into Microsoft Access spreadsheet which was later combined with the
information on donor genotyping for further analysis.

5.2.4

Donor genotyping

Donor DNA were extracted using either the Bromide salts (dodecyltrimethylammonium
bromide; DTAB/ cetyltrimethylammonium bromide; CTAB) method or using Roche
magnetic glass particle kits and Roche MagNA Pure extractors (Roche Molecular
Systems. Pleasanton, CA). Sanger sequencing and fragment length analysis were used to
determine the genotypes for the following KIM-1 coding variants: rs6149307,
rs45439103, and rs12522248. Genotyping was done by members of the Hegele Lab.
Donor genotypes were linked to the corresponding recipients in our de-identified
database.

5.2.5

Primary outcome definition

The primary outcome of the study was DGF, defined as requiring at least one session of
dialysis within the first 7 days post-transplantation [1, 5]. To determine the risk of DGF
with each genetic variant of KIM-1, the usage of relative risk was favored over odds
ratio.

5.2.6

Statistical analysis

Significance of the deviation of variant genotype frequencies from Hardy-Weinberg
equilibrium was assessed using chi-square analysis. Pairwise linkage disequilibrium
between HAVCR1 alleles was determined using Pearson correlation coefficients as
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described [35]. Recipients were grouped into subjects and controls based on donor
genotype. Throughout the study, the terms locus was used interchangeably with the
corresponding KIM-1 variants (Table 5-1), the term variant was used to describe the
defective KIM-1 allele, and wild-type was used to describe the non-defective reference
allele of KIM-1. Subjects were defined as being homozygous for each HAVCR1 variant
(rs12522248, rs45439103, rs6149307), while controls were defined as being
heterozygous for the respective variant or homozygous for the wild-type HAVCR1.
Baseline demographic and clinical variables were compared between subjects and
controls using student’s t-test for continuous variables and with Chi-squared test for
categorical variables. Differences in the rate of the primary outcome of DGF between
subjects and controls were assessed using univariate and multivariable logistic regression.
For the multivariable models, we adjusted for the following potential confounders: (donor
and recipient BMI, donor and recipient sex, history of hypertension, terminal creatinine,
type of donor (expanded criteria or not) and cold ischemia time [2, 5, 36-38]. This
exercise was repeated for each genotype comparison group. Results are expressed as
relative risk with 95% confidence interval (CI); p-values were derived from likelihood
ratio tests. All statistical analyses were performed using SAS version 9.4 (Cary, NC),
with a nominal level of significance defined as P < 0.05 (two-sided).
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5.3 Results
5.3.1

KIM-1 variants allele frequencies

We determined donor HAVCR1 (KIM-1) genotypes in a cohort of 627 deceased donor
kidney transplant recipients for three select functional (identified in Chapter 4)
polymorphisms (Table 5-1). Table 5-2 reports the observed genotype and allele
frequencies of the 3 variants in our population which were found to be in HardyWeinberg equilibrium corresponding to global population frequencies reported in
GeneCards. For both rs12522248 and rs45439103, the polymorphism coding for
impaired phagocytosis was less common. Surprisingly, for rs6149307, having the 5
amino acid deletion that impairs phagocytosis (see chapter 4) was more common (allele
frequencies 0.614) (Table 5-2).
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Table 5-1. Description of genotypes for the 3 KIM-1 variants studies.

Abbreviations: aa= Amino acid, - = Deletion, WW = Homozygous wild type, WV =
Heterozygous variant, VV= Homozygous Variant.

Table 5-2. Allele and Genotype frequencies of the 3 KIM-1 variants.

Abbreviation: Ref allele= Reference allele, Alt allele= Alternative allele. WW =
Homozygous wild type, WV = Heterozygous variant, VV= Homozygous Variant.
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5.3.2

Baseline Characteristics

Baseline donor, recipient and transplant patient demographics influencing DGF were
similar between subjects and controls for each KIM-1 variant, except for donor female
sex, donation after cardiac death (DCD) donor, panel reactive antibody (PRA) and
thymoglobulin induction therapy for subjects in the rs45439103 group (Table 5-3).
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Table 5-3. Baseline demographic characteristics according to KIM-1 variant
accession numbers.

Subjects = homozygous variant for each KIM-1 variant, Controls = heterozygous variant
and homozygous wild-type. N indicates the number, % indicates the percentage of the
study group exhibiting a particular characteristic. Means ± SD. Abbreviations: N/N =
Normal/Normal, N/D= Normal/Deletion, D/D= Deletion/Deletion, BMI= Body mass
index, PRA= Panel reactive antibody (peak), HTN= Hypertension, NS= Not significant.
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5.3.3

Primary Outcome: Rate of DGF

Of 627 individuals in our cohort, 165 developed DGF (26.3%). In univariate analysis,
DGF was not significantly different between subjects compared to controls (Table 5-4):
the relative risk of developing DGF for patients that received donor kidneys that were
homozygous for the polymorphisms at locus 1, locus 2 and locus 3 were 1.57 (95% CI =
0.97 – 2.53), 0.64 (0.25 – 1.65) and 1.01 (0.81 – 1.26), respectively. When we limited the
control group to recipients of donor kidneys with at least one copy of the wild-type allele
(at all 3 loci, N=203, see Table 5-7), the unadjusted relative risk did not change
appreciably from the primary analysis. Multi-variable adjusted analysis yielded similar
results (Table 5-4).
However, there was a trend to more DGF in patients who received donor kidneys
homozygous for the rs12522248 substitution allele compared to controls, but this did not
reach statistical significance (36% vs. 25.2%, unadjusted RR 1.57 (95% CI 0.97 – 2.53,
p=0.062). Adjusted analysis revealed a similar trend but was not statistically significant
(Table 5-4). Taken together, these findings suggest a potential risk of acquiring DGF
associated with donor kidneys that are homozygous for the rs12522248 variant.
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Table 5-4. Univariate and multivariate analysis for the deceased donors for the
occurrence of delayed graft function.

*Adjusted for: recipient age, recipient sex, recipient BMI (body mass index), and donor
age, donor sex, donor hypertension, terminal creatinine, cold ischemia time, and DCD
(donation after cardiac death)
Subjects = homozygous variant for each KIM-1 variant, Controls = heterozygous variant
and homozygous wild-type.
Abbreviation: N=Number, DGF= Delayed Graft Function, CI= Confidence interval, RR=
Relative risk.
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5.3.4

KIM-1 variant haplotype groups and definition

Linkage disequilibrium is defined as nonrandom association between alleles at 2 or more
loci [39]. Haplotypes under linkage disequilibrium have divergent frequencies compared
to the expected values when looking at independent alleles. Linkage disequilibrium is
said to be positive or negative, when 2 alleles occur together on the same haplotype
beyond or below expected values, respectively [40]. Therefore, rather than a single
variant being responsible for the association with an observed phenotype, it is possible
that one or more inherited variants that are co-expressed within the haplotype may be
contributing to the phenotype. Thus, to determine the cooperative consequence of KIM-1
haplotypes that get inherited together, we further dissected the prevalence of linkage
disequilibrium within our sample population (Table 5-5). We found that rs6149307 and
rs45439103 alleles are in close proximity and are in linkage disequilibrium with each
other.

Table 5-5. Linkage disequilibrium D’ values for KIM-1 variants.

Positive occurrence of linkage disequilibrium was determined by any D’ values > 0.36.
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Table 5-6 illustrates the haplotype groups with the presence or absence of mutation in
each locus exhibiting the variants that exist in a single chromosome, and the
corresponding frequencies observed in our cohorts. We then grouped the observed
haplotypes according to chromosome pairs (Table 5-7). Strikingly, of the 64 patients that
were homozygous variants for rs12522248 at locus 1 (Table 5-3), 56 patients expressed
both the rs12522248 homozygous variant allele at locus 1 and homozygous variant
rs6149307 allele at locus 3 on both chromosomes (Table 5-7).

158

Table 5-6. Definition and Frequencies of each Haplotype.

Numbers 1-5 represent distinct haplotype groups for a chromosome where 1 is N/N/N; 2
is N/N/D; 3 is N/D/N; 4 is C/N/N; 5 is C/N/D for the 3 loci with
rs125222248/rs45439103/rs6149307 respectively. N represents wild-type normal copy; D
represents deletion, and C represents T to C substitution as described in Table 5-1.
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Table 5-7. Haplotype Groups Definition in our Cohort and Frequencies.
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The sample population was grouped according to the KIM-1 haplotype distribution that
exist in the human population. Numbers 1-5 represent distinct haplotype groups for a
chromosome where 1 is N/N/N; 2 is N/N/D; 3 is N/D/N; 4 is C/N/N; 5 is C/N/D for the 3
loci with rs125222248/rs45439103/rs6149307 respectively (Table 5-6). N represents
wild-type normal copy; D or C represents a mutational event described in Table 5-1.
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5.4 Discussion
Kidney injury molecule-1 (KIM-1) is of particular interest in renal diseases due to its
transient expression on the renal proximal TECs upon injury in both mice and in humans
as well as its role in various renal diseases involving IRI [17, 19, 23, 41]. We have
previously reported the protective effect of KIM-1 in renal transplantation in mouse
models [23], however, whether our findings are translatable to patients was unknown and
thus remained an important question that needed to be answered. The genetic variability
of HAVCR1 is linked with various degrees of susceptibility to diseases such as asthma
and Hepatis A virus infection [25, 26, 28]. In Chapter 4, we identified 3 distinct genetic
variants affecting the coding region of KIM-1. The ensuing amino acid change(s)
resulting from the genetic variation significantly attenuated the phagocytic function of
KIM-1 (Chapter 4). To that end, we selected these 3 coding variants for this study with
the hypothesis that one or more of these variants that impair the function of KIM-1 would
lead to an increased risk of DGF. This hypothesis was based on previous work done by
the Bonventre laboratory [18, 22, 42] and our group [19, 21, 23] (including Chapters 2
and 3) suggesting that compromised clearance of dying cells would result in increased
tubular obstruction and necroinflammation, which in turn would further aggravate graft
damage and impair glomerular filtration, and ultimately lead to delayed graft function
[16, 43]. Using a large cohort consisting of 627 deceased donor-recipient pairs, we tested
whether one or more of the 3 donor coding variants of KIM-1 would predispose
transplant recipients to an increased risk of DGF.
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We report that compared to wild-type (“normal”) KIM-1, none of the recipients of donor
kidneys containing the KIM-1 variants were significantly associated with an increased
risk of DGF following renal transplantation. Interestingly, the patients who inherited a
kidney from a donor who was homozygous for rs12522248 exhibited 1.57 times greater
risk of developing DGF compared to everyone else in the cohort, but this did not reach
statistical significance. The DGF rate in this group was reached almost 36% compared to
25% in the controls group (Table 5-4). Notably, 56 of the 65 people who were
homozygous for this allele in our cohort were also homozygous for the rs6149307 allele
(Table 5-7), representing 9% of the population. It would be important to know if these
two simultaneous changes to the coding sequence of KIM-1 would further impair
phagocytic function when expressed in TECs compared cell expressing the rs6149307
variant (see Chapter 4). If so, it is plausible that having two phagocytic defects (i.e.
homozygous at 2 loci) may confer an increased risk of DGF. However, our study was not
powered to confirm this hypothesis, and further study is needed. Interestingly, males
(donors) are more likely to have the rs12522248 allele compared to females.
Animal data presented in Chapter 2 clearly showed that donor KIM-1 expression is
required for protection against graft dysfunction (“mouse DGF”) in mice. Given the
severity with which the rs6149307 affected KIM-1 function, if interpret the above data to
mean that patients receiving a kidney from donors carrying two copies of this alleles did
not experience any additional risk of DGF, this could imply that the phagocytic function
of KIM-1 is not required (or is redundant) for protection against DGF. If so, the nonphagocytic functions of KIM-1 in DGF may need to be examined more carefully. Indeed,
mutations in the IgV domain or the cytoplasmic domain can significantly alter KIM-1’s
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non-phagocytic function, but no variants that met our frequency criteria are known to
exist (GeneCards). Our lab has previously reported that the intracellular domain of KIM1 inhibits the harmful effects of activated G12 during IRI, ultimately enhancing kidney
repair [19, 21]. Consequently, non-synonymous variations in KIM-1 intracellular domain
that impede the interaction with G12 may lead to increased risk of DGF. The
cytoplasmic and IgV domains of KIM-1 have been shown to interact with the ligand
binding domain of pro-apoptotic nuclear receptor 77 (NUR77). This interaction did not
require the mucin domain of KIM-1 where our three coding variants are located. Through
this interaction, NUR77 is targeted for degradation, promoting epithelial cell survival
[44]. Mutations in the cytoplasmic or IgV domains of KIM-1 may impede the interaction
with NUR77 resulting in abrogation of NUR77 degradation and ultimately diminishing
the survival of TECs. Taken together, KIM-1 may protect against DGF via mechanisms
other than phagocytic clearance of apoptotic cells [22]. Identifying common nonsynonymous variants that alter the non-phagocytic function of KIM-1 could enable us to
test if they predispose to DGF development following renal transplantation.
In summary, in our cohort, we were not able to demonstrate that polymorphisms in any of
the 3 coding KIM-1 loci (rs12522248, rs45439103 and rs6149307) are associated with
increased risk of delayed graft function following renal transplantation. Our study was
limited by a relatively small sample size: <10% of donor kidneys were homozygous for
variant allele at rs12522248, and rs6149307. We did uncover that the variant allele for
rs6149307 was more common than the reference allele in the population (Table 5-2) and
that it is in linkage disequilibrium with the defective variant of rs12522248 making the
double mutant relatively common (Table 5-7). However, whether inheriting double
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mutations on KIM-1 on both alleles increases the risk of DGF requires further study.
Alternatively, it may be that the phagocytic function of KIM-1 alone does not play a
significant role in mitigating early allorecognition and rejection of the graft in humans,
but most likely a combination of multiple pathways is involved in the development of
DGF.
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6.1 Discussion
Renal transplantation is the optimal treatment for patients suffering from end-stage renal
disease [1, 2], however, ischemia-reperfusion injury (IRI) is an inescapable consequence
of transplantation that can limit the longevity of the kidney grafts [3-5]. The pathological
process of IRI is two-fold; firstly, ischemia is initiated when adequate blood flow is
restricted leading to decreased production of ATP, secondly reperfusion, which occurs
when the flow of oxygenated blood is restored, can induce burst of ROS production [6-8].
Renal tubular epithelial cells (TECs), which are highly susceptible to IRI, can either
overcome this insult leading to recovery or otherwise undergo various modes of cell
death [9-11]. The accumulation of dying cells in the microenvironment due to inefficient
clearance paves the way for secondary necrosis of apoptotic bodies. Although primary
and secondary necrotic cells exhibit different characteristics and morphology - secondary
necrotic cells are smaller in size and are depicted by the loss of chromatin, high levels of
monosodium urate microcrystals, and low ATP - they both lead to the release of DAMPs
(i.e. HMGB1; free, reduced form for primary and nucleosome bound and oxidized form
for secondary necrotic cells), which ultimately further exacerbates inflammation [9-11].
To add insult to injury, inflammation is progressively amplified via an auto-amplification
loop. Together, the culmination of this inflammatory cascade manifests as severe
secondary tissue damage [12]. Thus, targeting the efficient removal of dying cells in IRIimpacted kidneys may be a promising therapy for mitigating graft damage. In this thesis,
I outlined the protective mechanism of Kidney injury molecule -1 (KIM-1) against
transplant related -IRI in a murine model of renal transplantation. Moreover, with the aim
of translating our findings from the bench to the bedside, I also demonstrated how
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recombinant AIM can be used to enhance KIM-1 function to ameliorate DGF/tissue
damage and examined the effect of KIM-1 genetic variation in human patients in
predicting DGF following deceased donor renal transplantation. To this end, I elucidated
the importance of the phagocytic ability of KIM-1 in renal transplantation using in both
mice and in humans.

6.1.1

Kidney injury molecule-1 expression in donor kidneys
alleviate graft damage, renal dysfunction and graft failure
through mitigating necroinflammation following renal
transplantation

In Chapter 2, using a murine syngeneic renal transplant model, I determined the role of
donor kidney KIM-1 expression in transplant-associated graft damage. In these studies,
the donor kidneys were retrieved while the heart was still beating, therefore, our
transplant model most closely resembles transplants where the donors were deemed to be
neurological determination of death (NDD). I discovered that kidney KIM-1 expression
in the donor kidney significantly improved early graft function and improved overall
survival (Figure 2-1). In addition, KIM-1 expression mitigated graft damage and
decreased local and systemic inflammation (Figure 2-2 and 2-3). Interestingly, serum
levels of the danger signal, HMGB1, were elevated and increased M1 polarization of
macrophages were observed in recipients that received kidneys from KIM-1 deficient
mice compared to those who received kidneys from wild type mice (Figure 2-4 C-D).
Collectively, these findings suggest that KIM-1 mediated clearance of dying cells during
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syngeneic renal transplantation is required for limiting necroinflammation, ultimately
conferring a survival advantage. Although previous studies have delineated the protective
effect of KIM-1 in native kidney warm IRI [13, 14], my work is the first to define the role
of KIM-1 in renal transplantation, where both warm and cold ischemia occur
concurrently.
By using a syngeneic transplant model, we eliminated the potential confounding effect of
allogenic immune response, and thus we were able to elucidate the pathology strictly
stemming from IRI. The functional significance of KIM-1 in allogeneic transplantation,
however, is an important and clinically relevant question since human transplants occur
predominantly between HLA-mismatched donor and recipient pairs. Autotransplants are
done in cases of loin pain hematuria or mechanical issues pertaining to the ureter or renal
vasculature [15]. Notably, allogeneic transplants between HLA mismatched pairs exhibit
greater rejection and poorer overall survival compared to transplants between HLA
identical siblings [16]. Whether KIM-1 would also provide a protective benefit in the
context of allogenic transplants warrants further investigation.
Regulatory T cells (T regs), an important population responsible for suppressing
inflammation, has shown to be protective in kidney injury by participating in renal repair
following IRI [17], and by preventing transplant rejection through maintaining immune
tolerance [18-20]. Although danger signals are not strictly a prerequisite for graft
rejection, they may block tolerance induction via the inhibition of Tregs [21, 22]. The
inflammatory cytokine, IL-6, plays a key role in the blocking of Treg expansion [23, 24],
whereas IL-6 neutralization has been shown to enhance the proliferation of Tregs [25].
The production of IL-6 has been purported to be sourced from injured tubular epithelial
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cells following IRI and dendritic cells in response to DAMPs [22, 25]. In my model, I
observed increased levels of DAMPs (Figure 2-4 C) and IL-6 production (Figure 2-3 C)
in the recipients harboring KIM-1 deficient kidneys, which suggests a possible
mechanism by which KIM-1 could confer protection from alloimmune injury via the
promotion of Treg expansion.
Preconditioning is a protective clinical measure to render tolerance to severe IRI through
the application of brief episodes of ischemia and reperfusion to the organ prior to
transplantation [26]. A recent meta-analysis using experimental animal models reported
that ischemic preconditioning exhibited protected effects by reducing serum creatinine,
blood urea nitrogen, and histological damage following renal IRI compared to nontreated [27]. Similarly, Torras J et al. reported that a brief cycle of ischemic
preconditioning attenuated damage from renal transplant associated IRI in SpragueDawley rats [28]. It would be interesting to investigate the potential link between KIM-1
expression and preconditioning. It is possible that KIM-1 expression may be upregulated
during preconditioning and contribute to its protective phenotype.
The protective effects of transient KIM-1 expression during renal injury notwithstanding,
chronic expression of KIM-1 has been associated with regions of fibrosis, chronic
inflammation and progression of chronic kidney disease in human patients [29, 30].
Additionally, constitutive expression of KIM-1 in the absence of renal insult leads to
spontaneous development of renal fibrosis, renal failure and death in mice [31]. Taken
together, these findings highlight that a delicate balance limited KIM-1 expression is
necessary for optimal renal function and that therapies aimed to enhance KIM-1 function
must be cognizant of its proclivity towards pathogenicity.
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Although this dissertation has focused on the protective role of KIM-1 in renal
transplantation, it is true that transplant-associated pathologies can arise from diverse
aetiologies involving numerous pathways. Therefore, it is likely the case that a
combinational therapy that targets KIM-1 in addition to current clinical regimens, such as
immunosuppressants, may be the most ideal approach going forward. In this chapter, I
discovered that KIM-1 mitigates early graft inflammation and damage and increased
overall survival following renal transplantation by dampening necroinflammation through
phagocytosis of dying cells. My findings add to the body of work describing the role of
KIM-1 in kidney injury and provides a “stepping-stone” in delineating KIM-1 function in
long-term pathologies associated with allogeneic renal transplantation.

6.1.2

Recombinant apoptosis inhibitor of macrophage protein
ameliorates graft damage and renal dysfunction via
enhancement of KIM-1 mediated clearance of necrotic
cells following renal transplantation

In chapter 3, I examined the therapeutic potential of recombinant AIM (rAIM) in
mitigating graft damage following renal transplantation by enhancing the KIM-1
mediated removal of dying cells. Arai S et al. first described the protective role of AIM
administration in native kidney IRI, where they reported that AIM opsonized necrotic
cells were effectively cleared by KIM-1 [32]. This study suggested that the filtration of
endogenous AIM in the body is not maximized during kidney injury, and that additional
administration of exogenous AIM confers a therapeutic effect against kidney IRI. Here, I
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have shown that administration of rAIM in transplant recipient mice resulted in markedly
improved renal function and minimized graft damage (Figure 3-1). In addition, rAIM
treated mice released significantly less DAMPs into the circulation and displayed
decreased graft inflammation (Figure 3-2). Finally, we assessed whether rAIM would
potentiate the phagocytic ability of KIM-1 by enhancing the clearance of cellular debris.
As expected, I showed that the addition of rAIM to KIM-1 expressing human HEK 293
cells significantly increased the overall phagocytic activity in vitro (Figure 3-3D). Taken
together, my findings show that rAIM potentiates the functional activity of KIM-1 in the
clearance of necrotic cells which conferred a protective phenotype in the context of renal
transplantation.
Alloimmune injury is a major component of graft injury during renal transplantation
which is not addressed in syngeneic models [33]. Moreover, IRI has been found to
increase sensitization to donor alloantigens [5] and promote alloreactive CD4+ T cells
responses [34, 35] in allogeneic models of transplantation. Indeed, allogeneic
transplantation results in tissue damage to be incurred from both alloimmune responses
and IRI. In addition, autoantibodies (e.g. against LG3) can also aggravate IRI during
allotransplantation [36]. Thus, an important line of investigation is whether the rAIM
administration would similarly confer protection in an allogeneic transplant model where
alloimmune and autoimmune injuries significantly contribute to the overall pathology.
One limitation of this chapter is that it is unclear whether the protective effects attributed
to the administration of rAIM is solely mediated by KIM-1 and/or through the
enhancement of macrophage activity. Although Arai S et al. reported that in the absence
of KIM-1, administration of rAIM did not exhibit any protective effect following native
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renal warm IRI [32], whether rAIM will also be protective independent of KIM-1 in
transplant IRI needs further investigation. Notably, the original function of AIM was
identified to have pro-survival effects on macrophages [37]. Thus, how the presence of
additional exogenous AIM could contribute the survival and the recruitment of
macrophage to the kidney grafts and whether it exhibits additional protective effects
independent of KIM-1 by regulating macrophages needs to be further studied in detail.
Numerous studies have targeted various key molecules involved in necroinflammation in
attempt to block or abrogate the auto-amplification loop in order to mitigate kidney
damage [38]. In particular, Kumer S et al. described another DAMP, extracellular
histones, in the context of glomerulonephritis, exacerbated inflammation and kidney
damage, however DAMP neutralization markedly improved severe glomerulonephritis in
mice [39]. My own findings showed enhancing the clearance of dying cells via rAIM,
mitigated the release of DAMPs. Future investigations should examine whether rAIM
administration could stop the inflammatory feedback loop in an allogeneic model of renal
transplantation, which would ostensibly reduce the immunogenicity of the kidney graft
ultimately resulting in prolonged graft survival. Taken together with data from chapter 2,
my findings highlight the therapeutic application of rAIM to potentiate the protective
effects of KIM-1 in renal transplantation.
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6.1.3

The effect of genetic variations in human Kidney injury
molecule-1 in altering its phagocytic function and in
predicting delayed graft function

In chapter 4, I uncovered that 3 HAVCR1 variants that altered the region encoding for the
mucin domain of KIM-1 all significantly impaired its (apoptotic cell) phagocytic function
compared to wild-type KIM-1 in vitro. Interestingly, the total protein levels of each
variant when expressed in HEK 293 cells remained unaltered. However, there was some
variability in the relative cell-surface expression of each variant compared to cells
expressing wild-type KIM-1 (Figure 4-2). Furthermore, out of the 3 variants, rs6149307
exhibited greatest reduction in its phagocytic ability of apoptotic target cells compared to
the wild-type (Figure 4-3).
Considering that KIM-1 has a critical role in ameliorating graft damage and renal
dysfunction in kidney transplantation (Chapter 2) [40], coupled with the finding that
variations in the coding region result in impaired phagocytic activity (Chapter 4), the next
question was to assess whether donor kidneys that were positive for the select variants
examined in Chapter 4 predisposes recipients to an increased risk of DGF. In Chapter 5,
logistic regression analysis of a clinical database revealed that none of these variants
were significantly correlated with increased risk of DGF (Table 5-4). However, our
cohorts that inherited kidneys from donors homozygous for rs12522248 allele exhibited
increased DGF rate and 1.664 times greater risk of developing DGF compared to the
control groups (Table 5-4). Thus, taken together with the increased DGF rate observed in
the 64 patients with homozygous mutation in rs12522248, and 56 patients of these
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patients exhibiting 2 significant defects in loci on both chromosomes (double mutants),
this group of cohorts therefore may be an interesting group and requires further study.
KIM-1 expression has been reported to be correlated with renal function and fibrosis
following renal transplantation [41]. DGF, although an important indicator of
transplantation prognosis, is only one of many clinical factors that may influence a
transplant’s success. It may also be of interest to examine the potential association of
each KIM-1 variant with risk of long-term graft survival since KIM-1 expression is
known to correlate with fibrosis and progression to CKD [31, 42, 43].
The contribution of necrotic cell death to IRI and DGF is another factor that could have
confounded our multivariate analysis. Indeed, the predominant form of cellular injury
during renal IRI is believed to be via necroptosis [44, 45]. Although, we showed that
genetic polymorphisms in select KIM-1 variants resulted in defective clearance of
apoptotic cells (Chapter 4), whether these variants also were defective in its ability to
bind to AIM on opsonized necrotic cells was not tested. Therefore, it is possible that
these select variants still retained the ability to clear necrotic cells which would render a
negligible association with DGF.
Although Chapter 5 took sex into consideration when determining the risk of DGF with
the three functional KIM-1 variants, Chapters 2 and 3 of my thesis only examined the
role of KIM-1 in the donor kidneys of male mice. Numerous studies have implicated that
males are more prone to IRI and consequently exhibit poorer transplant outcomes
compared to females [46, 47]. In addition, when subjecting mice and rats to bilateral
ischemia reperfusion injury, males developed significantly greater amount of kidney
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deterioration, renal dysfunction and severe tubular necrosis compared to females [48, 49].
Administration of testosterone exacerbated damage due to renal IRI in females. Similarly,
estrogen administered to castrated males provided significant protection [50]. Taken
together, these results propose that testosterone is a key determinant for enhanced
susceptibility to IRI. Therefore, examining the potential for sex differences in the role of
KIM-1 in kidney transplants is an interesting question and needs further investigation.
Here we show for the first time that 3 select variations in the coding region of KIM-1
causes alteration in cell surface expression and significantly attenuates its phagocytic
function. However, whether these select variants are predictive for the potential risk of
developing DGF require additional studies. Although further analysis of the data is
necessary in uncovering potential associations with clinical prognostic markers, these
findings may provide novel insight in potentially linking the non-phagocytic function of
KIM-1 with long-term transplant outcomes in human patients.
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6.2 Conclusion
The overarching theme of this thesis is to examine the role of KIM-1 in mitigating graft
damage in the hopes of providing evidence for potential therapies that would prolong the
lifespan of the transplanted kidney. Ischemia reperfusion injury is a major element that
limits the lifespan of the kidney grafts [3, 4, 6, 7, 51, 52] and delayed graft function is a
major consequence of IRI which
in turn is associated with graft rejection and poor long-term survival [53, 54]. This thesis
systematically describes how efficient clearance of dying cells could markedly improve
transplant outcomes via regulating necroinflammation that occurs downstream of KIM-1
(Figure 6-1). First, I identified KIM-1 as a target protein in mitigating graft injury which
consequently improved overall survival. Second, I validated a KIM-1 specific therapy,
rAIM, as a potential treatment agent in transplantation. Finally, I assessed the clinical
significance of various KIM-1 haplotypes in human kidney transplantations. There are
still unanswered questions including: the role of KIM-1 in an allogeneic transplantation;
whether chronic expression of KIM-1 following renal transplantation is pathogenic; and
whether genetic variants of KIM-1 in donor kidneys predispose human recipients to
chronic kidney disease and subsequent graft failure. Nevertheless, this thesis elucidates
the protective role of KIM-1 and rAIM administration during renal transplantation, and
highlights the effective targeting of KIM-1 to be an attractive therapeutic strategy that
may prolong kidney transplant survival.
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Figure 6-1. Expression of KIM-1 in the donor kidneys protects against transplant
associated-IRI through regulation of necroinflammation via the clearance of dying
cells.
Abbreviations: AC = Apoptotic cell, AIM= Apoptosis inhibitor of macrophage protein,
IRI= Ischemia-reperfusion injury, NC= Necrotic cell.
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